Serum response factor-dependent regulation of smooth muscle gene transcription by Chen, Meng
SERUM RESPONSE FACTOR-DEPENDENT REGULATION OF SMOOTH 
MUSCLE GENE TRANSCRIPTION 
 
 
 
 
 
 
 
Meng Chen 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements  
for the degree 
Doctor of Philosophy 
in the Department of Cellular and Integrative Physiology,  
Indiana University 
 
October 2013 
ii 
Accepted by the Faculty of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
                   
     B. Paul Herring, Ph.D., Chair 
 
                   
     Patricia J. Gallagher, Ph.D. 
Doctoral Committee 
                   
                      Irina Petrache, M.D. 
 September 5, 2013 
 
                   
     Simon J. Rhodes, Ph.D. 
 
                   
     Johnathan D. Tune, Ph.D. 
 
 iii 
ACKNOWLEDGEMENTS 
 
First and foremost, with my deepest and sincerest appreciation and gratitude, I 
would like to thank my mentor, Dr. B. Paul Herring, for granting me the great 
opportunity to study in the lab, for giving me tremendous support throughout my 
Ph.D. study and for guiding me toward becoming an independent scientist. 
Especially, his patience, meticulousness and serious attitude toward science, not 
only influenced me during my stay here, but also will benefit me for my whole life. 
I am very grateful for his continuous support and excellent guidance, and I could 
not have imagined having a better mentor. 
 
I am truly grateful for all the help from my committee members: Dr. B. Paul 
Herring, Dr. Patricia J. Gallagher, Dr. Irina Petrache, Dr. Simon J. Rhodes and 
Dr. Johnathan D. Tune. They are always there to support me and to write me 
recommendation letters no matter how busy they are. I sincerely appreciate their 
time, insightful discussion, constructive comments and tremendous support. 
 
I would like to thank American Heart Association for awarding me the pre-
doctoral fellowship. It was one of the most joyful days when I knew I got the 
fellowship and it made me feel so good and encouraged when my work and 
proposal finally got recognized. 
 
 iv 
I would like to thank my brilliant collaborators: Dr. Johnathan D. Tune, Dr. Susan 
J. Gunst, Dr. Ghassan S. Kassab, Dr. Wenwu Zhang, and Dr. Xiao Lu. 
 
I also would like to thank my labmates and individuals from Gallagher lab: April 
Hoggatt, Min Zhang, Ketrija Touw, Rebecca Jones, Jiliang Zhou, Emily Blue, 
Ryan Widau, Liguo Zhang, for their collegiality and most importantly their 
friendship. I am truly grateful to have the chance to work with all of them. 
 
I am very thankful to my friends outside the department: Cong Xu, Jie Xie, Ru Yi, 
Xu Han, Yang Liao and Raquel Salvador for their friendship and I did enjoy your 
accompany during my stay in Indy. I am also grateful to my friends in Beijing: 
Huaxia Chen, Yingjie Yu, and Chan Huang, with whom I spent the five years of 
the precious college time and developed life-long friendship. 
 
I also would like to thank my parents and younger sister. I feel loved and so lucky 
to have them behind myself all the time. Without their unconditional love and 
unwavering support, I would not have gone so far in pursuing the science career.  
 
Last but not least, I would like to thank my husband Fuguo Jiang. He is the 
person who always made me feel happy inside no matter what happened and 
words are never enough to express my deepest and heartfelt love to him.  
 
I am also grateful to life. “Science is not easy”, but life is good. 
 v 
ABSTRACT 
Meng Chen 
 
SERUM RESPONSE FACTOR-DEPENDENT REGULATION OF SMOOTH 
MUSCLE GENE TRANSCRIPTION 
 
Several common diseases such as atherosclerosis, post-angioplasty restenosis, 
and graft vasculopathies, are associated with the changes in the structure and 
function of smooth muscle cells. During the pathogenesis of these diseases, 
smooth muscle cells have a marked alteration in the expression of many smooth 
muscle-specific genes and smooth muscle cells undergo a phenotypic switch 
from the contractile/differentiated status to the proliferative/dedifferentiated one. 
Serum response factor (SRF) is the major transcription factor that plays an 
essential role in coordinating a variety of transcriptional events during this 
phenotypic change. The first goal of my thesis studies is to determine how SRF 
regulates the expression of smooth muscle myosin light chain kinase (smMLCK) 
to mediate changes in contractility. Using a combination of transgenic reporter 
mouse and knockout mouse models I demonstrated that a CArG element in 
intron 15 of the mylk1 gene is necessary for maximal transcription of smMLCK. 
SRF binding to this CArG element modulates the expression of smMLCK to 
control smooth muscle contractility. A second goal of my thesis work is to 
determine how SRF coordinates the activity of chromatin remodeling enzymes to 
control expression of microRNAs that regulate the phenotypes of smooth muscle 
 vi 
cells. Using both mouse knockout models and in vitro studies in cultured smooth 
muscle cells I showed how SRF acts together with Brg1-containing chromatin 
remodeling complexes to regulate expression of microRNAs-143, 145, 133a and 
133b. Moreover, I found that SRF transcription cofactor myocardin acts together 
with SRF to regulate expression of microRNAs-143 and 145 but not microRNAs-
133a and 133b. SRF can, thus, further modulate gene expression through post-
transcriptional mechanisms via changes in microRNA levels. Overall my research 
demonstrates that through direct interaction with a CArG box in the mylk1 gene, 
SRF is important for regulating expression of smMLCK to control smooth muscle 
contractility. Additionally, SRF is able to harness epigenetic mechanisms to 
modulate expression of smooth muscle contractile protein genes directly and 
indirectly via changes in microRNA expression. Together these mechanisms 
permit SRF to coordinate the complex phenotypic changes that occur in smooth 
muscle cells. 
 
     B. Paul Herring, Ph.D., Chair 
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CHAPTER I 
INTRODUCTION 
 
A. Overview of smooth muscle 
 
Smooth muscle is traditionally classified as either multi-unit or single-unit. In 
multi-unit smooth muscles, each muscle fiber operates independent of each 
other and usually is innervated by a single nerve ending. Examples of this type of 
smooth muscle include the ciliary muscle of the eye, the iris of the eye and the 
piloerector muscle that causes erection of hair. In single-unit smooth muscle, a 
whole group of smooth muscle cells function together as a single unit. The cells 
are aggregated into bundles and their cell membranes are adherent to each 
other. In addition, their cell membranes are joined by many gap junctions through 
which ions can pass from one cell to another to facilitate coordinated contraction 
of a group of smooth muscle fibers. Because this type of smooth muscle 
occupies the walls of most viscera of the body, such as gastrointestinal tract, bile 
duct, genitourinary tract, uterus, bladder and some blood vessels, they are also 
often called visceral smooth muscle [1].  
 
Unlike skeletal and cardiac muscle, smooth muscle is not striated. In striated 
muscles, actin and myosin filaments are highly organized into sarcomeres, that 
give rise to the alternating light bands that contain only actin filaments, and dark 
bands that consist of both myosin filaments and overlapping actin filaments 
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(Figure 1). However, in smooth muscles, although there are both actin and 
myosin filaments with similar but not exactly the same properties as those in 
striated muscle, they are not organized into sarcomeres. Instead, the actin 
filaments are attached to dense bodies that are either attached to the cell 
membrane or dispersed inside the cell, while the myosin filaments are 
interspersed among the many actin filaments, lacking the regularity of striated 
muscle, as shown diagrammatically in Figure 1.  
 
B. Smooth muscle contraction 
 
Similar to striated muscles, smooth muscle cells (SMCs) contract in response to 
the movement of actin and myosin filaments that is stimulated by a rise in 
intracellular calcium ions. However, the way that calcium ions stimulate the 
movement of actin and myosin filaments is distinct between striated and smooth 
muscle tissues. In striated muscles, calcium ions act via the troponin-
tropomyosin complex to trigger contraction. In contrast, smooth muscle cells do 
not have troponin but rather have a high concentration of calmodulin, another 
calcium binding protein. In smooth muscle, when levels of intracellular calcium 
ions rise, they bind to calmodulin and the calcium-calmodulin complex then 
activates myosin light chain kinase (MLCK), which phosphorylates serine 19 of 
the 20kDa regulatory light chain of myosin. Phosphorylation of myosin light chain 
stimulates the actin-activated ATPase activity of myosin, thereby starting the 
attachment-detachment crossbridge cycle and triggering the contraction of 
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smooth muscle cells. During relaxation, a decrease in intracellular calcium ion 
concentration results in attenuation of MLCK activity and myosin light chain 
phosphatase de-phosphorylates the myosin light chains (Figure 2). As MLCK is 
crucial for controlling smooth muscle contractility, alterations in MLCK expression 
are associated with diseases that affect this process. For example, alterations in 
MLCK expression are involved in a variety of pathologies, including colitis [2], 
inflammatory bowel disease [3], asthma [4,5], inflammatory lung disease [6], 
familial aortic dissection [7] and hypertension [8,9]. Because of the importance of 
MLCK expression levels in physiological and pathological processes, it is 
important to understand the transcriptional mechanisms that govern MLCK 
expression. Experiments described in Chapter II will identify the key 
transcriptional pathways that regulate MLCK expression in vivo in mice to control 
smooth muscle contractility. 
 
C. Smooth muscle origins 
 
Smooth muscle cells in different tissues have very diverse embryonic origins. It is 
generally accepted that smooth muscle cells in most abdominal organs are 
derived from local mesoderm or mesothelium during embryogenesis [10]. The 
origins of vascular smooth muscle cells are particularly heterogenous [11]. 
Lelievre and Le Douarin revealed that smooth muscle cells of aortic arch, ductus 
arteriosus, and pulmonary artery originate from neural crest through their 
pioneering studies on chimeric quail-chick embryos. More specifically, they 
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showed it is the cranial neural crest rather than trunk neural crest or 
mesencephalic neural crest, that is competent to form smooth muscle cells in 
these specific vascular regions [12]. More recently, analysis of transgenic 
reporter mice has suggested that smooth muscle cells in the desending aorta are 
derived from somites, not lateral plate mesoderm [13]. In contrast, coronary 
smooth muscle cells have been shown to derive from the proepicardium, which is 
a transient villous structure formed from the splanchnopleural mesoderm of the 
posterior heart field. Through cellular lineage tracing, Mikawa and Gourdie 
reported that the proepicardium contains a population of coronary smooth muscle 
progenitor cells that migrate into the heart. In addition to coronary smooth muscle 
cells, data from lineage tracing showed that proepicardial cells also give rise to 
epicardium, coronary endothelium and cardiac fibroblasts [14,15]. Furthermore, 
several studies have suggested that some vascular smooth muscle cells arise 
from endothelial cells or endothelial progenitor cells. For example, DeRuiter et al. 
reported that quail embryonic endothelial cells labeled by wheat germ agglutinin-
gold particles relocalize to subendothelial layer after 19 hours of incubation and 
express smooth muscle marker smooth muscle alpha-actin [16]. Yamashita et al. 
demonstrated that the Flk1-positive embryonic stem cells are a type of vascular 
progenitor cell and they can give rise to both endothelial cells and mural cells, 
forming vascular structure in chick embryo [17].   
 
D. Smooth muscle phenotypes 
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In contrast to skeletal muscle and cardiac myocytes that are terminally 
differentiated, smooth muscle cells are highly plastic and exhibit a spectrum of 
phenotypic states ranging from robustly synthetic/proliferative smooth muscle 
cells to the highly contractile/fully differentiated mature cells. In normal adult 
tissues, smooth muscle cells are quiescent and express high levels of contractile 
proteins permitting them to control tissue contractility. During the pathogenesis of 
atherosclerosis, post-angioplasty restenosis, and graft vasculopathies, smooth 
muscle cells undergo a phenotypic switch from the contractile state to a 
dedifferentiated, proliferative state in response to a variety of stimuli. The 
terminology of smooth muscle cell phenotypic modulation was first introduced in 
1979, by Campbell et al., based on the observation that a majority of mitotic 
smooth muscle cells contain reduced myofilament bundles and increased 
cytoplasmic organelles such as free ribosomes and rough endoplasmic reticulum 
(ER). Thus, they proposed that modulation of the differentiated phenotype is a 
prerequisite for smooth muscle cell proliferation [18]. Although the initial 
identification of smooth muscle cell phenotype depended largely on 
morphological criteria, over the past several decades, its definition has expanded 
to encompass alterations of structure, function and gene expression. Fully 
differentiated contractile smooth muscle cells are spindle-shaped, rich in 
myofilaments in the cytosol and nonproliferative with low levels of migration, 
while smooth muscle cells of a dedifferentiated proliferative phenotype are 
characterized with fewer myofilament bundles and being active in synthesis, 
secretion, migration as well as mitosis.  
   6 
 
Although smooth muscle cells switch from differentiated to proliferative 
phenotype during the pathogenesis of many diseases, smooth muscle 
differentiation and proliferation are not necessarily mutually exclusive processes. 
For example, mouse embryonic smooth muscle cells, before embryonic day 18-
20, exhibit very fast replication (75%-80% per day) and have the ability to 
proliferate under serum-deprived conditions [19], yet at this time the smooth 
muscle cells are also actively inducing smooth muscle differentiation gene 
expression [20]. Conversely, SMCs within advanced atherosclerotic lesions show 
low rates of proliferation, yet have reduced expression of smooth muscle 
differentiation markers [21]. Therefore, the cessation of proliferation alone is not 
sufficient to promote smooth muscle differentiation and there must be other 
additional factors involved in initiating smooth muscle differentiation [22]. 
 
In adults, it is traditionally accepted that dedifferentiated proliferating smooth 
muscle cells that are seen under pathological conditions have arisen from the 
previously fully differentiated mature smooth muscle cells. However, there are 
also reports that these pathological smooth muscle cells may arise from a variety 
of stem cells and smooth muscle progenitor cells. Several studies have shown 
that bone marrow derived cells, probably hematopoietic stem cells or circulating 
smooth muscle progenitor cells, can contribute to the dedifferentiated smooth 
muscle cell population in the neointima following vascular injury [23,24,25,26]. 
Recently, a new type of progenitor cell, named a multipotent vascular stem cell, 
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which expresses markers such as Sox10, Sox17 and S100β, has been identified 
in the vascular walls [27]. In response to vascular injury, these multipotent 
vascular stem cells, not pre-existing differentiated smooth muscle cells, were 
shown to proliferate and contribute to the neointima formation [27]. Since this 
conclusion challenges the long-standing paradigm that the dedifferentiation of 
smooth muscle cells from contractile to proliferative status plays an important 
role in vascular remodeling, it has evoked an intense debate on this controversial 
topic among a group of leaders in the smooth muscle pathology field [28,29]. 
 
E. Smooth muscle differentiation markers 
 
To better discriminate the different states of smooth muscle cells, many smooth 
muscle cell-specific differentiation markers have been investigated. This analysis 
has revealed that most smooth muscle differentiation markers are not exclusively 
specific to smooth muscle cells. Instead they are transiently expressed in other 
cell types. Reported smooth muscle selective markers include: smooth muscle 
alpha-actin (SM α-actin), SM22α, telokin, smooth muscle myosin heavy chain 
(SM MHC), calponin, aortic carboxypeptidase-like protein (ACLP), desmin, h-
caldesmon, meta-vinculin, and smoothelin [22,30,31]. Some of these smooth 
muscle markers are discussed in more detail below. 
 
SM α-actin is the most widely used smooth muscle marker and fortunately there 
are several highly selective antibodies for this protein available commercially. It is 
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expressed in smooth muscle at a very early stage and it is the first specific 
protein known to be expressed during smooth muscle cell development [32]. In 
addition, it is the most abundant protein in differentiated smooth muscle cells 
comprising up to 40% of total cellular protein [33]. However, it is not specifically 
expressed in smooth muscle cells and is expressed in a variety of non-smooth 
muscle cells under certain conditions, such as striated muscle cells during 
development [34], fibroblast cells during wound healing [35], endothelial cells 
during vascular remodeling and its expression remains high in dedifferentiated 
smooth muscle cells [36]. 
 
SM22α is a 22kDa smooth muscle cell-restricted protein that physically 
associates with actin filaments in contractile smooth muscle cells although its 
physiological function is unclear. A gene knockout study suggested it is not 
required for the basal functions mediated by vascular or visceral SMCs during 
mouse development [37].  Although SM22α is restricted to smooth muscle cells 
in adult tissues, it is transiently expressed in skeletal muscle and cardiac muscle 
during embryogenesis [37,38]. Compared with smooth muscle α-actin, SM22α 
starts to appear a little later around embryonic day 9.5 during embryonic 
development [39].  
 
Telokin is a 17kDa protein transcribed from an independent intronic promoter 
within the mylk1 gene. Telokin plays a role in calcium de-sensitization of smooth 
muscle contraction [40,41,42]. It is a very specific marker for smooth muscle 
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differentiation, although its expression in vascular smooth muscle is much lower 
than that in visceral smooth muscle. 
 
SM MHC is perhaps the most discriminating marker for smooth muscle cell 
characterization. Using in situ hybridization at different mouse embryonic stages, 
it was shown that SM MHC transcripts begin to appear in early developing aorta 
at embryonic day 10.5, then in the gut, lung, peripheral blood vessels at day 12.5, 
and in esophagus, ureter as well as bladder at day 17.5. No SM MHC transcripts 
were observed in non-smooth muscle tissues during embryogenesis [43]. 
Consistent with these data, a lacZ reporter driven by the SM MHC promoter plus 
the first intron was highly specifically expressed in mouse smooth muscle tissues 
in vivo [44]. Furthermore, fate mapping studies using mice with Cre recombinase 
(Cre) driven by the SM MHC promoter/enhancer crossed with Cre-dependent 
lacZ reporter mice also demonstrated complete smooth muscle cell specificity, 
except for a small population of cells within the right atrium at embryonic day 8.5. 
These cells may represent transiently differentiated SMCs in the process of 
epithelial-mesenchymal transformation from proepicardial cells into coronary 
smooth muscle cells [45]. Overall these data suggest that currently SM MHC is 
the most specific marker of the smooth muscle cell lineage. 
 
F. Transcription factors/cofactors and SMC genes 
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In order to understand how numerous stimuli affect the phenotypes of smooth 
muscle cells during SMC pathogenesis, it is necessary to study the 
transcriptional pathways that drive expression of smooth muscle differentiation 
markers. Tremendous progress has been made in this area as summarized in 
Figure 3 [46]. Among all the transcription factors known to regulate smooth 
muscle cell differentiation, serum response factor (SRF) is perhaps the most 
central and best studied one.  
 
i. SRF and the SRF response element 
 
SRF was named based on its binding activity to a serum response element 
whose core sequence is CC(A/T)6GG and is required for the expression of the 
immediate early response gene, c-fos, after serum stimulation. In 1985, Treisman 
found that a 5’ proximal segment of the human c-fos promoter was required for 
its rapid upregulation following growth factor stimulation [47,48]. Further studies 
identified a 22-bp element (AGATGT CCATATTAGG ACATCT) having inverted 
repeat of dyad symmetry within that region. Since the element binds to a protein 
in HeLa cell nuclear extracts harvested after serum stimulation, it was named 
serum response element [47,49,50]. Meanwhile, Minty and Kedes performed a 
comparative promoter analysis of human, rat, mouse and chicken cardiac alpha-
actin genes and found a strikingly conserved common element CC(A/T-rich)GG 
named CCArGG box [51]. The CCArGG box (abbreviated as CArG box) is the 
core sequence of the serum response element. Although the terms serum 
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response element and CArG box are sometimes used interchangeably, the 
serum response element contains not only a CArG box but also a binding site for 
ETS (E-twenty six) transcription factors [52]. As described later, it is in fact the 
ETS transcription factors that are the direct sensors of growth factor signaling 
cascades activated by mitogen-activated protein kinase (MAPK).  
 
To predict the location of all possible CArG boxes within the human genome, the 
Miano group performed a genome-wide screen in an attempt to define the 
functional mammalian “CArGome”. Comparative genomic analysis between 
human and mouse, uncovered more than 100 hypothetical genes that include at 
least one CArG box within 4kb upstream from their transcription start sites. Out of 
the 89 genes that were manually selected and cloned, 60 target genes were 
validated by at least two methods, including luciferase reporter assays, gel shift 
assays, chromatin immunoprecipitation assays, and changes in mRNA 
expression following RNAi knockdown of SRF. Remarkably, Gene Ontology 
categorization of CArG element-containing genes revealed that almost half of the 
validated genes are associated with the actin cytoskeleton or contractile 
apparatus [53]. Moreover, analysis of 33 smooth muscle cell-restricted genes 
(Figure 4) showed that 23 genes have one or more evolutionarily conserved 
CArG boxes, with a total of 37 CArG boxes usually within 2-3kb of the 
transcription start sites [54]. This finding probably reflects the requirement for 
SRF to be relatively close to the RNA polymerase in order to activate 
transcription. Consistent with this, SRF was shown to interact with the RAP74 
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subunit of TFIIF in the RNA polymerase II holoenzyme and disruption of the 
interaction impaired SRF activated transcription [55]. Furthermore, analysis of the 
frequency of nucleotides in the 37 conserved CArG boxes from the 33 smooth 
muscle cell-restricted genes, revealed some of the highly conserved 
charateristics adopted by regulatory CArG boxes in smooth muscle specific 
genes: (1) The most highly conserved nucleotides are the known contact points 
for SRF (AT -4/-5 and +4/+5). (2) There appears to be a preference for T at -2 
and +1 and A at +2 and +3. (3) Most of the flanking nucleotides are more or less 
evenly distributed, although there is a bias for T at -8, G at +10, A or C at -9 and  
-15, C or G at -7, -10 and +13, and G or T at +9 and +11 (Figure 4) [54].  
 
Many of the highly conserved CArG boxes located in the promoter regions of 
smooth muscle contractile genes have been validated to be important for gene 
transcription both in vitro and in vivo. For example, transgenic mice generated 
using a 310bp telokin promoter fragment that includes one CArG element had 
smooth muscle-specific reporter gene expression similar to that of the 
endogenous telokin gene, however, mutation of the CArG box completely 
abrogated the transgene expression [56]. 
 
Some smooth muscle cell-restricted genes have multiple CArG boxes in their 
promoters that are not of equal importance for gene transcription. For example, 
the SM α-actin gene harbors two CArG-like elements 5’ of the transcription start 
site and a consensus CArG box in intron1. The two proximal 5’ CArG elements 
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were shown to be important for SMC-specific activity in cultured cell lines in vitro 
[57]. However, transgenic mice harboring the proximal SM α-actin promoter 
sequences that included both of these elements (up to -2800bp) only directed 
lacZ transgene expression in cardiac and skeletal muscle, but not in SMCs, 
suggesting the two 5’ CArG elements may not be sufficient for SM α-actin 
expression in SMC in vivo. In contrast, a transgene driven by the promoter region 
together with the first intron essentially recapitulated the endogenous expression 
pattern. Within this transgene, mutation of the distal 5’ CArG abolished promoter 
activity, while mutation of the proximal 5’ CArG box only had a mild effect. 
Interestingly, mutation of the intronic CArG box specifically abolished its activity 
in SMCs without affecting expression in striated muscles, suggesting that the 
intronic CArG box of the SM α-actin gene may determine its smooth muscle cell-
restricted expression [58]. While most SMC-specific genes have one or more 
CArG boxes in their regulatory regions, some however do not have any 
evolutionarily conserved CArG elements within 10kb upstream of their 
transcription start sites. This implies the existence of alternative mechanisms 
directing the smooth muscle specificity, although these have not yet been 
described in detail.  
 
SRF is a founding member of the MADS (the name refers to the names of 
originally identified members: Mcm1 in yeast, Agamous and Deficiens in plants, 
and SRF in animals) domain-containing family of transcription factors. The 
amino-terminus (N-terminus) of SRF comprises a basic DNA-binding domain, a 
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dimerization domain and an interface for protein-protein interactions [59], while 
the carboxyl-terminus (C-terminus) of SRF contains a strong transactivation 
domain with phosphorylation sites that signal the recruitment of SRF-associated 
factors [60]. SRF binds to CArG boxes as homodimer. The primary DNA-binding 
element is an anti-parallel coiled coil of two amphipathic α-helices that were 
aligned parallel to the minor groove in the center of CArG sequence. The DNA 
molecule wraps around the coiled coil allowing the basic amino of the α-helices 
to fit into the DNA major groove (Figure 5) [61].  
 
SRF is an essential transcription factor for mammalian mesoderm formation. 
Whole body SRF knockout mice have arrested gastrulation development at about 
embryonic day 7 and have a complete loss of mesoderm. Activation of SRF-
dependent immediate early response genes such as egr-1, c-fos and early 
smooth muscle marker SM α-actin were severely impaired in knockout embryos 
[62]. Several groups have generated tissue-specific SRF knockout mice in order 
to circumvent the embryonic lethality of the global SRF knockout mice. Heart-
specific deletion of SRF using a beta MHC-driven Cre transgene resulted in 
lethal cardiac defects between E10.5 and E13.5 including abnormally thin 
myocardium, dilated cardiac chambers, poor trabeculation, and a disorganized 
interventricular septum [63]. Deletion of SRF in cardiac and smooth muscle cells 
by SM22-Cre mediated excision, also resulted in embryonic death around E11.5 
[64]. Similarly, deletion of SRF using alpha MHC-Cre caused embryonic lethality 
by E12.5 due to cardiac insufficiency [65]. Furthermore, tamoxifen induced SRF 
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deletion in the heart of adult mice led to dilated cardiomyopathy and death from 
heart failure after 10 weeks of treatment [66]. In skeletal muscle, knockout of 
SRF using Cre recombinase resulted in perinatal lethality due to 
dysmyofibrillogenesis in skeletal muscle [67]. Tamoxifen induced deletion of SRF 
in adult smooth muscle cells caused both vascular and visceral abnormalities. In 
the vasculature there was decreased contractile response, reduced smooth 
muscle contractile proteins and abnormal vascular tone [68]. In the GI tract SRF 
knockout resulted in impaired intestinal contractility, defective intestinal 
peristalsis and decreased SMC contractile protein expression [69,70]. Overall 
these data strongly demonstrated that SRF is an absolutely critical transcription 
factor for muscle differentiation.  
 
Although SRF is expressed at high levels in smooth muscle tissues, SRF is a 
ubiquitous transcription factor. Genes mediating two largely opposite processes-
proliferation and differentiation, can both possess CArG boxes that are regulated 
by SRF. Hence expression of SRF alone cannot explain how it orchestrates cell-
specific programs of gene expression. It has been reported that several 
mechanisms may be involved in regulating SRF activity in cell context-dependent 
manner, such as its association with cofactors, posttranscriptional modification of 
SRF, variations in SRF binding affinity among different CArG boxes, number, 
position and spacing of CArG boxes, as well as the chromatin conformation of 
CArG elements [46]. For the purposes of my research I will focus mainly on the 
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regulation of SRF activity in SMCs through interaction with SRF transcription 
cofactors and chromatin remodeling enzymes. 
 
ii. SRF transcription cofactors 
 
Among all the SRF transcription cofactors, myocardin is one of the most 
important for SMC differentiation [71]. Myocardin was first discovered in an 
attempt to search for cardiac unique genes and its expression is restricted to 
cardiac and smooth muscles. Through interacting with the MADS domain of SRF, 
myocardin and SRF-CArG boxes form a ternary complex that transactivates 
several cardiac and smooth muscle-specific genes, such as calponin, SM MHC, 
SM α-actin, and SM22α, however it does not significantly activate growth 
response genes such as c-fos [71,72]. Myocardin knockout mice die by 
embryonic day 10.5 with no evidence of aortic smooth muscle cell differentiation, 
indicating that myocardin is required for vascular smooth muscle differentiation 
[73]. Myocardin is thus a tissue-restricted transcription cofactor that helps to 
explain SRF’s ability to direct SMC-restricted gene expression. 
 
Two myocardin related transcription factors, MRTFA/megakaryoblastic leukemia 
1 (MKL-1) and MRTFB/MKL-2, have been identified to have similar domain 
structure as well as transcriptional activity to myocardin [74,75]. Myocardin and 
MRTFs all belong to the SAP domain family, which is named for SAF-A and B 
(nuclear scaffold attachment factors A and B), Acinus, a caspase-3-activated 
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protein required for apoptotic chromatin condensation, and PIAS, a protein 
inhibitor of activated STAT (signal transducer and activator of transcription) [76]. 
As schematically depicted in Figure 6, the N termini of myocardin family 
members contain conserved domains named RPEL domains. However, the 
diverged RPEL domains in myocardin as compared to the MRTFs permit 
myocardin to be localized exclusively in the nucleus. In contrast, MRTFA and 
MRTFB bind to actin through their RPEL motifs, resulting in their cytoplasmic 
localization under unstimulated conditions [77]. Myocardin binding to SRF is 
mediated through the B1 domain located between the conserved basic and 
glutamine-rich domains of myocardin. The SAP domain is highly conserved 
among myocardin family members, although its physiological function is not clear. 
The C-terminus of myocardin family members contains a very strong 
transcriptional activation domain. Distinct from the cardiac and smooth muscle 
cell-restricted expression pattern of myocardin, MRTFs are ubiquitously 
distributed. Although MRTFs are not specifically localized to SMCs, both MRTFA 
and MRTFB play important roles in SMC differentiation. MRTFA-null mice have a 
defect in myoepithelial cell differentiation with attenuated SMC contractile 
proteins such as SM α-actin, SM MHC, calponin and tropomyosin [78,79]. 
Additionally, MRTFB knockout mice die during embryonic development with a 
spectrum of cardiac outflow defects [80,81]. Mechanistically, it has been reported 
that regulation of MRTFs shuttling between cytoplasm and nucleus is critical for 
the smooth muscle-specific effects by these molecules. For example, activation 
of Rho signaling promotes the assembly of F-actin from monomeric G-actin, thus 
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the lower concentration of free G-actin in the cytosol increases the accumulation 
of MRTFs to nucleus, where MRTFs associate with SRF and activate 
transcription of SMC differentiation genes [77].  
 
iii. Regulation through combination of transcription factors/cofactors 
 
The MADS domain of SRF is a docking site for many other transcription 
cofactors, such as homeodomain proteins Barx1b [82] and Nkx3.2 [83], the zinc 
finger protein GATA6 [83]. Although each of these proteins can form a stable 
ternary complex with SRF-CArG DNA, these cofactors are not SMC restricted, 
nor can they discriminate CArG boxes within differentiation marker genes from 
immediate early response genes. However, it has been reported that SRF, 
Nkx3.2 and GATA6 together cooperatively activate several SMC marker genes, 
including SM22, but not c-fos [83], implying that combination of several 
transcription factors or cofactors may provide a mechanism for a general 
transcription factor such as SRF to control SMC-specific genes selectively.  
 
Numerous signaling pathways converge on the key transcription factor SRF. 
Constant integration of these many signals present in the local environment, in 
aggregate, determines the gene expression pattern as well as the phenotypic 
status of smooth muscle cells, as summarized in Figure 7 [22]. Although 
relatively little is known about the factors regulating smooth muscle cell 
phenotypes in vivo, many studies in cultured SMCs suggested that a great 
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variety of factors, including mechanical forces [84], extracellular matrix 
components such as collagen [85,86,87], endothelial-SMC interaction [88], 
neuronal factors [89], reactive oxygen species [90], contractile agonists such as 
vasopressin and angiotensin II [91,92], TGF   [93,94], and platelet-derived growth 
factor-BB (PDGF-BB) [95,96] are able to modulate the expression of SMC 
differentiation markers in the cultured cell systems. As a coordinator of numerous 
transcriptional events, SRF is able to integrate different signals influencing SMC 
phenotypes through its ability to form unique complexes with other transcription 
cofactors. For example, PDGF stimulation of smooth muscle cells activates a 
MAPK signaling cascade, leading to phosphorylation of Elk1, a ternary complex 
factor (TCF) of the ETS-domain family. Phosphorylated Elk1 then forms stable 
ternary complex with SRF on the ETS binding site located adjacent to CArG 
boxes, replacing myocardin from the CArG boxes of SMC genes, thus repressing 
SMC differentiation genes expression [97,98]. At the same time, the 
phosphorylated Elk1/SRF complex also binds to CArG elements in growth-
responsive genes such as c-fos, egr1, inducing their transcription and thereby 
causing SMC proliferation. In addition to increasing phosphorylated Elk1, PDGF 
stimulates expression of Krüppel-like transcription factor 4 (Klf4), a transcriptional 
repressor that antagonizes myocardin-induced activation of SMC genes via 
binding to G/C-rich cis-acting sequence in the transcriptional regulatory regions 
controlling SMC contractile genes [99,100]. Since most of these data were 
derived from observations of in vitro cell culture models, these conclusions 
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should be interpreted with caution as in vitro smooth muscle cell culture systems 
might not fully recapitulate the in vivo environment.  
 
G. Chromatin remodeling and SMC genes 
 
In eukaryotic cells, DNA is compacted 5000-fold into chromatin and 
compartmentalized in the nucleus. The basic unit of chromatin is the nucleosome, 
which is comprised of 146 base pairs of double stranded DNA wrapping around 
two copies of histones H2A, H2B, H3 and H4. As a result of this complicated 
packaging, regulation of DNA accessibility is an important first step for the 
binding of transcription factors/cofactors during gene transcription. Using 
chromatin immunoprecipitation (ChIP) assays, it was revealed that SRF has a 
preferential binding to the promoter CArG boxes of SMC genes with enhanced 
histone H3 or H4 acetylation [101]. Moreover, signals such as vascular injury 
recruit Klf4-dependent histone deacetylase (HDAC) activity to SMC gene 
promoters, resulting in loss of SRF binding and promoting the dedifferentiated 
phenotype. In contrast, in the absence of Klf4, SRF is able to recognize 
accessible CArG box sequences within the “open” chromatin containing 
acetylated histone H4, synergizing with myocardin recruited histone H3 Lysine4 
di-methylation (H3K4dMe), to promote transcription of SMC genes and SMC 
differentiation [102,103].  
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Chromatin conformation changes are generally controlled by at least three 
mechanisms: DNA methylation, histone modifications and chromatin remodeling 
by ATP-dependent chromatin remodeling complexes. ATP-dependent chromatin 
remodeling complexes are comprised of four families in mammals, SWI/SNF 
(SWItch/Sucrose NonFermentable), INO80 (chromatin-remodeling ATPase 
INO80), ISWI (Imitation SWI), and CHD (chromodomain helicase DNA binding 
protein) complexes that are able to regulate the conformation of nucleosomes by 
utilizing the energy of ATP [104,105]. Of all the ATP-dependent chromatin 
remodeling complexes, the SWI/SNF complex is the best-characterized one. It 
consists of 8-11 components, encoded by 20 different genes with possibly a total 
of 288 predicted assemblies, forming a very stable complex. SWI/SNF 
complexes contain one of two alternative ATPases, Brahma-related gene 1 
(Brg1) or Brahma (Brm). Both of these proteins are ubiquitously expressed in 
almost all tissues, and have both redundant and distinct functions in regulating 
gene expression. For instance, Brg1 can slow down growth of tumor cell lines 
and induce differentiation, whereas Brm has little effect [106]. Brg mutant mice 
die early in embryonic development due to growth arrest of the inner cell mass 
and trophoblast [106], while Brm-null mice are slightly larger than normal [107]. 
Although Brg1 appears to have some functions that cannot be performed by Brm, 
several groups have shown that in some situations Brm is able to compensate for 
Brg1, partially or completely. For example, either Brg1 or Brm containing 
SWI/SNF complexes can support the ability of myocardin or MRTFA to induce 
expression of smooth muscle-specific genes [108,109]. Although, knockout of 
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Brg1 alone in smooth muscle resulted in decreased expression of smooth 
muscle-specific contractile proteins and impaired GI contractility this phenotype 
was worse in mice also lacking Brm [110]. These data suggest that Brg1-
containing SWI/SNF chromatin remodeling complexes and their interactive 
transcription factors play an essential role in regulating SMC genes expression 
and smooth muscle phenotypes. 
 
H. MicroRNAs in smooth muscle cells 
 
Recent studies have suggested that altered microRNA expression contributes to 
SMC phenotypic changes. MicroRNAs are endogenous small (~22nt) non-coding 
RNA that can target mRNA for degradation or repress mRNA translation by base 
pairing with the 3’-untranslated region of targeted mRNA. MicroRNA biogenesis 
is initiated when primary microRNAs are transcribed by RNA polymerase II. 
Primary microRNAs contain stem-loop structures and are long, ranging in length 
from a few hundred to thousands of nucleotides. Primary microRNAs are cleaved 
by RNase III Drosha and its partner DGCR8, into microRNA precursors that are 
then transported to cytoplasm by Exportin 5. The RNase Dicer recognizes the 
precursors in the cytoplasm and processes them to mature microRNA duplexes. 
The mature microRNA which is about 22 nucleotides long, is assembled into an 
RNA-induced silencing complex (RISC) which directs microRNA binding to the 
3’-UTR complimentary sequence of targeted mRNAs, either decreasing mRNA 
stability, or inhibiting protein translation [111].  
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Smooth muscle-specific Dicer knockout mice have decreased microRNA 
expression and exhibit embryonic lethality, associated with extensive internal 
hemorrhage, dilated thin-walled blood vessels, decreased smooth muscle cell 
proliferation, diminished expression of smooth muscle contractile proteins, and 
loss of actin stress fibers [112] [113]. Moreover, tamoxifen-induced deletion of 
Dicer specifically in smooth muscle cells of adult mice caused a dramatic 
reduction of smooth muscle contractile markers and blood pressure [114]. These 
studies reveal critical roles for microRNAs in the development and maintenance 
of SMCs. 
 
While Dicer-deficient mice reflected the collective functions of numerous miRNAs 
in smooth muscle cells, several specific microRNAs have been shown to play 
roles in the regulation of smooth muscle cell proliferation and differentiation. The 
most highly studied microRNAs in smooth muscle are microRNA-143 (miR-143) 
and miR-145 [115,116,117,118,119]. The miR-143 and miR-145 are two mature 
microRNAs that arise from the same primary transcript. Mice lacking both miR-
143 and miR-145 are viable and do not display overt abnormalities in smooth 
muscle differentiation. However, neointima formation in response to vascular 
injury was profoundly affected in mice lacking these microRNAs [118,119]. 
Several putative targets of miR-143/145 have been identified. MiR-145 targets 
multiple transcription factors that are involved in vascular SMC differentiation, 
such as Klf4, CamKIIδ (Ca2+/calmodulin-dependent protein kinases IIδ) and 
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myocardin. Interestingly, miR-145 suppresses the levels of Klf4 and CamKIIδ, 
two negative regulators of SMC differentiation but increases the expression of 
myocardin, a strong positive regulator of differentiation, consistent with miR-145 
promoting the contractile phenotype of vascular SMCs [117]. Unlike smooth 
muscle-specific deletion of Dicer, loss of miR-143/145 is not embryonic lethal 
indicating that other miRNAs are also involved in SMC differentiation. In addition 
to miRs-143/145, miR-21 has been reported to promote proliferation and inhibit 
apoptosis of vascular SMCs by down-regulating phosphatase and tensin 
homolog (PTEN) and up-regulating B-cell lymphoma 2 [120]. MiR-221 was also 
found to increase proliferation and reduce the levels of VSMC contractile proteins 
[121,122]. Recently, miR-133, which is conventionally considered as a cardiac or 
in vitro skeletal muscle specific microRNA, has been shown to inhibit VSMC 
proliferation and after balloon injury in vivo, at least partially through regulating 
the expression of Sp1 and moesin [123]. Several other miR-133 targets have 
been identified that are involved in the regulation of cell proliferation and 
differentiation, such as SRF and cyclin D2 [124,125].  
 
Although microRNAs are now recognized as intriguing regulators of vascular 
SMC phenotypic modulation, little is known regarding the transcriptional 
regulation of microRNA in smooth muscle cells. The observation that miR-
143/145 and miR-133 were all up-regulated in differentiated and down-regulated 
in de-differentiated smooth muscle cells suggests that the known transcriptional 
regulators of smooth muscle differentiation may be also responsible for the 
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regulation of these microRNAs. In addition, the SWI/SNF chromatin remodeling 
complex has been shown to be required for miR-133 expression in skeletal 
muscle together with the transcription factors myogenin and myoD [126,127]. 
Experiments described in Chapter III of my thesis begin to unravel the genetic 
and epigenetic mechanisms that regulate the microRNA expression in smooth 
muscle cells.  
 
I. Rationale 
 
Serum response factor is the major transcription factor that plays an essential 
role in coordinating a variety of transcriptional events during smooth muscle cell 
phenotypic changes. SRF forms transcriptional complexes with myocardin or 
other transcription cofactors and recruits chromatin remodeling enzymes to CArG 
boxes in the regulatory regions of smooth muscle specific genes, thereby 
activating their transcription. These functions of SRF are intergrated together with 
the activities of several microRNAs that are involved in regulating SMC gene 
expression via post-trancriptional mechanisms. Therefore my thesis work mainly 
focuses on 1) determining the role of CArG elements in regulating expression of 
smooth muscle myosin light chain kinase, a key protein that regulates SMC 
contractility and 2) determining the transcriptional and epigenetic mechanisms 
that regulate microRNA expression in smooth muscle cells.  
 
During these studies I tested two central hypotheses: 
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1. A CArG element within intron 15 of the mylk1 gene is required to specifically 
modulate transcription of the 130kDa smMLCK. 
2. SRF and myocardin recruit SWI/SNF remodeling complexes to the promoters 
of the miRs-143/145 and miR-133 genes to stimulate microRNA expression in 
differentiated SMCs. 
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Figure 1. Diagrams show the arrangement of actin and myosin in skeletal 
and smooth muscle cells. 
A. In skeletal muscle cells, actin and myosin filaments are organized into 
sarcomeres, giving rise to the alternative light bands that contain only actin 
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filaments, and dark bands that consist of both myosin filaments and the 
overlapped part of the actin filaments. 
B. In smooth muscle cells, the actin filaments are attached to dense bodies that 
are either attached to the cell membrane or dispersed inside the cell, while the 
myosin filaments are interspersed among the many actin filaments, lacking the 
regularity of striated muscle structure. 
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Figure 2. Processes for smooth muscle cell contraction and relaxation 
When the intracellular calcium ions concentration is high, calcium ions bind to 
calmodulin and the calcium-calmodulin complex then activates myosin light chain 
kinase (MLCK), which phosphorylates the serine 19 of the 20kDa regulatory light 
chain of myosin. Phosphorylation of myosin light chain allows the myosin head to 
bind to actin, thereby triggering the contraction of smooth muscle cells. Reversal 
of the contraction process requires myosin phosphatase that is able to de-
phosphorylate myosin light chain and detach the actin-myosin binding, thus 
relaxing smooth muscle cells. 
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Transcription Factors Known or Likely to be Involved in Regulation of SMC 
Differentiation/Proliferation 
 
Transcription Factor Target Genes 
MADS Box Proteins 
 
SRF 
MEF2B 
 
 
Increase numerous SMC differentiation markers 
Increase SM MHC 
Homeodomain Proteins 
 
Phox1/Mhox 
Barx1b 
Barx2b 
Nkx3.1 
Nkx3.2 
Hox B7 
Gax (Mox2) 
 
 
Increase SM α-actin 
Increase β-tropomyosin 
SMC specific targets unknown 
Increase SM γ-actin 
Increase SM22, caldesmon 
Increase SM22, calponin 
Increase p21, decrease proliferation 
GATA family 
 
GATA 4/5/6    Increase numerous SMC differentiation markers 
Increase p21, decrease proliferation 
Myocardin 
 
Increase numerous SMC differentiation markers 
Zinc Finger Protein 
 
Sp1/3 
Klf4 
Klf5 
 
 
Decrease SM MHC, SM22 
Decrease SM22, SM α-actin 
Increase SM22 
Helix-Loop-Helix Protein 
 
USF 
Gridlock 
HAND1 
HAND2 
Id2/3 
Twist 
 
 
Increase SM α-actin 
SMC specific targets unknown 
SMC specific targets unknown 
SMC specific targets unknown 
Decrease p21, increase proliferation 
Decrease SM22 
Single-Stranded DNA 
Binding Proteins 
 
Purα, Purβ, MSY1 
 
 
 
Decrease SM α-actin 
Others 
 
Egr1 
 
 
Increase proliferation (numerous targets) 
   31 
TEF1 
SSRP1 
Mrf2 
AP1 
YY1 
P53 
c-myb 
CRP1/2 
NFATc1 
Increase SM α-actin 
Increase SM22 
Increase SM α-actin, SM22 
Increase osteopontin 
Increase SM22 
Increase SM α-actin 
Increase SM α-actin 
SMC specific targets unknown 
Increase SM MHC 
 
 
Figure 3. Transcription factors that are involved in the regulation of smooth 
muscle cell phenotypic modulation 
(Adapted from “Combinatorial control of smooth muscle-specific gene expression” 
by Kumar, M.S. and G.K. Owens, 2003, Arterioscler Thromb Vasc Biol, 23, p. 
737-47) 
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Figure 4. Analysis of the 33 smooth muscle specific genes and the 37 CArG 
boxes from their regulatory regions 
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The position of each nucleotide relative to core CArG box is indicated numerically 
at the top. The numbers in the lower part represent the times and frequency 
when each indicated base occurs across the 37 CArG sequences. 
(Adapted from “Serum response factor: toggling between disparate programs of 
gene expression” by Miano, J.M., 2003, J Mol Cell Cardiol, 35, p. 577-93) 
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Figure 5. The structure of SRF-DNA binding complex 
A. View perpendicular to the molecular two-fold axis and overall DNA helix axis 
B. View following the axis of two SRF α-helices, revealing the slab-like structure 
of SRF monomers 
C. View down the molecular two-fold axis 
The two SRF monomers, distinguished in red and green, have highly similar 
conformation; DNA is in purple. The primary DNA-binding element is an anti-
parallel coiled coil of two α-helices that were aligned parallel to the minor groove 
in the center of CArG sequence. The β-sheet packs above the α-helices and is 
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the central element for homodimerization. The C-terminus contains one short α-
helix for each SRF monomer.   
(Adapted from “Structure of Serum Response Factor Core Bound to DNA” by 
Pellegrini, L., T. Song, and T.J. Richmond, 1995, Nature, 376: p. 490-498)
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Figure 6. Schematic representation of myocardin and myocardin-related 
transcription factors 
The mouse myocardin gene encodes 935 and 865 amino acid protein isoforms 
by alternative splicing, with 935-aa isoform predominately in the heart, and 865aa 
largely in SMCs.The domain structures are designated as labeled in the 
schematics.  
The numbers on the right indicate the number of amino acids for each protein. 
The locations of the RPEL, basic (+), glutamine-rich (Q), SAP, LZ, and TAD 
domains are shown in gay or black rectangles. RPEL domains regulate actin 
binding in MRTF-A and MRTF-B, yet in myocardin these domains do not bind 
actin. The basic and glutamine-rich domains are required for SRF binding. LZ 
domain regulates homo- and heterodimerization with other MRTF family 
members. 
(Adapted from “Actin dynamics control SRF activity by regulation of its 
coactivator MAL” by Miralles, F., et al., 2003, Cell, 113, p. 329-42) 
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Figure 7. The phenotypic state of smooth muscle cells is highly plastic and 
dependent on integration of mutiple local environmental cues.  
This figure summarizes the extrinsic factors that are reported to be important in 
the regulation of SMC differentiation states. Importantly, smooth muscle cells can 
exhibit a broad range of phenotypic states depending on the variable expression 
levels of smooth muscle-specific differentiation markers. The SMC cartoon on left 
depicts the highly synthetic/proliferative SMC and the one on the right represents 
the highly contractile fully differentiated/mature SMC.  
Two separate pathways are depicted because it is not clear if all the transitions in 
phenotypes follow the same pathway. The top arrows increase in size depict that 
the expression levels of smooth muscle differentiation markers such as smooth 
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muscle alpha-actin and SM MHC increase from left to right, while the lower 
arrows increase in size from right to left are to show that markers for more 
immature SMCs are more expressed in the cells on the left. There is controversy 
as to if bone marrow-derived progenitor cells (BMC, the dashed cell) are capable 
of becoming fully differentiated SMCs (as indicated by the question mark and the 
dashed arrows). 
PDGF, platelet-derived growth factor; ET, endothelin; TGF, transforming growth 
factor; ROS, reactive oxygen species; NO, nitric oxide; EC, endothelial cells. 
(Adapted from “Molecular regulation of vascular smooth muscle cell 
differentiation in development and disease” by Owens, G.K., M.S. Kumar, and 
B.R. Wamhoff, 2004, Physiol Rev, 84, p. 767-801) 
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CHAPTER II 
REGULATION OF 130KDA SMOOTH MUSCLE MYOSIN LIGHT CHAIN 
KINASE EXPRESSION BY AN INTRONIC CARG ELEMENT 
 
A. Summary 
 
The mylk1 gene encodes a 220kDa nonmuscle myosin light chain kinase (MLCK), 
a 130kDa smooth muscle MLCK (smMLCK), as well as the non-catalytic product 
telokin. Together these proteins play critical roles in regulating smooth muscle 
contractility and changes in their expression are associated with many 
pathological conditions. It is thus important to understand the mechanisms 
regulating expression of mylk1 gene transcripts. Previously we reported a highly 
conserved CArG element, which binds serum response factor, in intron 15 of 
mylk1 [128]. As this CArG element is close to the promoter that drives 
transcription of the 130kDa smMLCK, we examined its role in regulating 
expression of the 130kDa smMLCK. Results showed that deletion of the intronic 
CArG region from a β-galactosidase reporter gene abolished transgene 
expression in mice in vivo.  Deletion of the CArG region from the endogenous 
mylk1 gene, specifically in smooth muscle cells, decreased expression of the 
130kDa smMLCK by 40% without affecting expression of the 220kDa MLCK or 
telokin. This reduction in 130kDa smMLCK expression resulted in decreased 
phosphorylation of myosin light chains and attenuated smooth muscle 
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contractility. The mice with reduced 130kDa smMLCK expression also exhibited 
a 24% decrease in the length of their small intestines that was associated with a 
significant reduction of Ki67-positive smooth muscle cells in neonatal mice. 
Overall these data show that the CArG element in intron 15 of the mylk1 gene is 
necessary for maximal expression of the 130kDa smMLCK and that the 130kDa 
smMLCK isoform is specifically required to regulate smooth muscle contractility 
and small intestine smooth muscle cell proliferation.   
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B. Introduction 
 
Myosin light chain kinases (MLCKs) are encoded by four distinct genes, mylk1-4.  
The expression of the mylk4 gene is poorly characterized, whereas mylk2 and 
mylk3 genes produce MLCK isoforms that are primarily expressed in skeletal 
muscle and cardiac muscle cells, respectively [129,130]. In contrast, the products 
of mylk1 gene are expressed at highest levels in smooth muscle tissues but also 
detectable in many, if not all, tissues and cell types [131]. The mylk1 gene is a 
large gene spanning ~250kb and comprising 31 exons [132]. It encodes at least 
three protein products: a 220kDa MLCK, a 130kDa MLCK, and a non-catalytic 
gene product, telokin. Each transcript from the mylk1 gene is derived from a 
unique independent promoter within the gene [132]. The 220kDa MLCK is also 
referred to as nonmuscle MLCK or endothelial MLCK, as it was first 
characterized in chick embryo fibroblasts and endothelial cells [133,134]. The 
130kDa MLCK is also called the smooth muscle MLCK (smMLCK), as it is most 
abundant in smooth muscle cells, although it is widely expressed in other tissues 
at lower levels [132,135,136]. Telokin is a non-catalytic product of the gene that 
is expressed at very high levels in intestinal, urinary, and reproductive tract 
smooth muscle, at low levels in vascular smooth muscle cells and undetectable 
levels in other tissues [137]. 
 
Both the 220kDa and 130kDa MLCK can phosphorylate serine 19 of the 20kDa 
myosin regulatory light chain (RLC) of smooth muscle and nonmuscle myosin II, 
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in the presence of Ca2+ and calmodulin. In smooth muscle cells, phosphorylation 
of the myosin regulatory light chain is an obligatory step for the initiation of 
contraction. In many other cell types, phosphorylation of RLC induced by MLCK 
is important for regulating actomyosin-based cytoskeletal functions such as focal 
adhesion and stress fiber formation, secretion, cytokinesis, neurite growth cone 
advancement, endothelial and epithelial barrier formation and cell migration 
[138,139,140,141,142,143,144]. Alterations in MLCK expression have been 
linked to a variety of pathologies, including colitis [2], inflammatory bowel disease 
[3], asthma [4,5], inflammatory lung disease [6], familial aortic dissection [7] and 
hypertension [8,9]. However, the specific functions of the various MLCK isoforms 
in these processes are not clear. Global knockout of the 220kDa MLCK in mice 
results in numerous defects in epithelial and endothelial barrier function 
suggesting that this isoform has a specific role in regulating these processes 
[145,146,147,148,149]. Through specific targeting of a portion of the catalytic 
domain shared by the 220 and 130kDa MLCKs, it has been possible to 
determine the roles of these kinases in specific tissues and cell types [150]. As 
anticipated, ablation of both MLCK isoforms in smooth muscle cells resulted in 
impaired contractility and decreased myosin light chain phosphorylation [8,150]. 
Surprisingly, deletion of both 220kDa and 130kDa MLCK specifically from 
endothelial cells had very little effect on vascular permeability, bringing into 
question the importance of endothelial cell expressed MLCK in regulating 
endothelial barrier function [151]. This surprising finding may suggest that the 
220kDa MLCK may be important for regulating endothelial barrier function via 
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another cell type rather than being important directly only in endothelial cells. 
Because of the overlapping structure of the 220kDa and 130kDa MLCK it is 
difficult to specifically examine the function of the 130kDa MLCK without also 
affecting expression of the 220kDa isoform. To begin to address this issue we 
examined regulatory elements that specifically regulate expression of the 130kDa 
MLCK with the idea that deletion of these elements may attenuate expression of 
the 130kDa MLCK without effecting expression of the other products of the mylk1 
gene. Toward this goal we previously identified a promoter within the mylk1 gene 
that specifically directs expression of the 130kDa MLCK [128]. Within this 
promoter there is a conserved CArG element that binds to serum response factor 
(SRF) and is required for myocardin-induced expression of the 130kDa MLCK 
[128]. 
 
The CArG element, CC(A/T)6GG, is the cis-regulatory element that binds serum 
response factor (SRF), an evolutionarily conserved MADS (MCM1, agamous, 
deficiens, SRF) domain-containing transcription factor. SRF binding and crystal 
structure studies have shown that a functional CArG element can deviate by no 
more than 1 bp from the consensus sequence [152]. Virtually all known CArG 
elements reside within 4 kb of the transcription start site of genes [152]. 
Integrating computational algorithm prediction approaches with experimental 
validation, a genome-wide screen identified 60 target genes that are regulated by 
CArG elements. Among them, 26 of the validated SRF target genes encode for 
cytoskeletal/contractile or adhesion proteins [52,152]. When bound to a CArG 
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element, SRF also provides a docking surface for interaction with numerous 
accessory co-factors to form ternary complexes, conferring tissue-specific 
expression of target genes. For example, ternary complexes of SRF and Elk1 are 
important for growth factors regulation of immediate early genes such as c-fos 
[153]. In smooth muscle cells, ternary complexes of SRF together with myocardin 
or myocardin related transcription factors are very powerful activators of 
numerous smooth muscle-specific contractile and regulatory proteins such as the 
130kDa MLCK [72]. In the promoter region of the 130kDa smMLCK (located in 
intron14 of mylk1 gene), a highly conserved CArG element has been shown to 
play a pivotal role in regulating 130kDa smMLCK expression. SRF and its 
coactivator myocardin enhanced the activity of this promoter and induced 
expression of the 130kDa smMLCK in 10T1/2 fibroblast cells, while GATA-6 
repressed promoter activity, possibly through disrupting SRF-myocardin 
complexes [128]. Besides the CArG element in the promoter region of the 
130kDa MLCK, there is another highly conserved CArG element in the first intron 
of the 130kDa smMLCK (intron15 of mylk1 gene). Chromatin 
immunoprecipitation assays confirmed that this intronic CArG element also binds 
to SRF in smooth muscle cells [128]. However, the previous studies did not 
determine if this intronic CArG element effects the expression of the 130kDa 
smMLCK in vivo. In the current study, we found that the intronic CArG element is 
important for regulating expression of transgenes driven by the 130kDa smMLCK 
promoter in vivo and for driving expression of endogenous 130kDa smMLCK in 
mice. Moreover, we show that targeting this element is an effective means to 
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specifically decrease expression of the endogenous 130kDa smMLCK without 
affecting expression of the 220kDa MLCK or telokin. 
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C. Methods 
 
i. Generation of targeting vector for homologous recombination 
 
The targeting vector was generated by inGenious Targeting Laboratory (Stony 
Brook, NY). A 7.56kb fragment containing about 5.1kb extending 5’ and 2.16kb 
extending 3’ to the intronic CArG region, was subcloned from a C57BL/6 BAC 
clone (RP23: 55O1, Source BioScience, Nottingham, UK) into pSP72 vector 
(Promega, Fitchburg, WI). To construct the targeting vector for homologous 
recombination, a loxP/FRT flanked Neo cassette was inserted 54bp 3’ of the 
intronic CArG element (smMLCK: +1696-+1705), and a single loxP site 
containing engineered Afl II and BamH I sites for southern blot analysis was 
inserted 184bp 5’ of the intronic element.  
 
ii. Generation of transgenic reporter mice 
 
The 130kDa smMLCK promoter, exon 1, intron 1 and portion of exon 2 were cut 
from the pGL2B construct described previously [128] and ligated into the pWhere 
LacZ reporter vector (InvivoGen, San Diego, CA). SW105 bacteria (NCI-
Frederick, MD) that has a flippase recombinase (Flp) inducible gene were 
transformed with the targeting vector described above and cultured at 32°C. L-
arabinose (A3256, Sigma-Aldrich, St. Louis, MO) induced flippase recombinase 
gene expression was used to excise the Neo cassette from the targeting vector. 
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The resulting plasmid was digested by Fse I and Pml I (NEB, Ipswich, MA), 
yielding a 2.3kb fragment that included the intronic CArG element and 
surrounding loxP sites. The smMLCK-389~+8427 pWhere vector was also cut by Fse 
I and Pml I. The resulting 2kb fragment that included the intronic CArG element 
was replaced with the corresponding 2.3kb fragment isolated from the targeting 
vector to generate the ICArG-smMLCK-389~+8427 pWhere plasmid. The integrity of 
the plasmid was confirmed by restriction enzyme digestion and DNA sequencing. 
In order to delete the CArG element from the ICArG-smMLCK-389~+8427 pWhere 
plasmid, this plasmid was electroporated into SW106 bacteria (NCI-Frederick, 
MD) which has a Cre combinase (Cre) inducible gene. L-arabinose-induced Cre 
expression in SW106 cells at 32°C resulted in excision of the loxP flanked 
intronic CArG region to generate plasmid ΔICArG-smMLCK-389~+8427 pWhere. 
Correct excision of the CArG element was confirmed by DNA sequencing. ICArG-
smMLCK-389~+8427 pWhere and ΔICArG-smMLCK-389~+8427 pWhere plasmids were 
linearized and microinjected into pronuclei of fertilized oocytes by standard 
procedures by the Indiana University School of Medicine transgenic mouse 
facility. Neonatal founder mice were genotyped for the presence of the transgene 
and were analyzed at one month old by β-galactosidase staining as described 
previously [154]. All animal experiments were conducted under the approval of 
Indiana University School of Medicine Institutional Animal Care and Use 
Committee.  
 
iii. Generation of knockout mice  
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The intronic CArG region floxed mouse was generated by inGenious Targeting 
Laboratory (Stony Brook, NY). The targeting construct was linearized using NotI 
(NEB, Ipswich, MA) prior to electroporation into C57BL/6N embryonic stem cells. 
Positively selected ES cells were screened by PCR and then expanded for 
southern blot confirmation of targeting. Correctly targeted ES cells were 
microinjected into BALB/c blastocysts. Resulting chimeras with a high 
percentage black coat color were mated to C57BL/6 Flp mice to remove the Neo 
cassette. The deletion of Neo cassette was screened and confirmed by PCR and 
DNA sequencing. The germline transmited floxed mouse was shipped to Indiana 
University School of Medicine Laboratory Animal Resource Center (LARC) and 
quarantined for two months. Then the floxed mouse was mated to smooth 
muscle myosin heavy chain driven Cre mouse (smMHC-Cre mouse) that was 
kindly provided from Dr. Michael Kotlikoff at Cornell University, to delete the 
intronic CArG region specifically in smooth muscle tissues. Genotyping primers 
for the floxed mice are: flox F: GGC AAG CCA AAC CCT TAC ACA G, flox R: 
GAC TGG AGA TAA CCT CCT CTC ACT 
 
iv. Contractility measurement of isolated colon rings 
 
Colon was isolated and cleaned gently. The proximal part of the colon was cut 
into rings about 0.5 cm in length and mounted onto steel supports, submerged in 
a 5-ml organ bath with physiological saline solution (PSS) saturated with 95% 
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O2-5% CO2 at 37°C, as described previously [155]. PSS solution contains 119 
mM NaCl, 25 mM NaHCO3, 4.7 mM KCl, 2 mM CaCl2, 1.17 mM KH2PO4, 1.17 
mM MgSO4, and 5.5 mM glucose, pH 7.4. A 1.5-g preload passive tension on 
these colon rings was empirically determined to result in the optimal contraction 
after 60 mM KCl (P9541, Sigma-Aldrich, St. Louis, MO) stimulation. The passive 
tension was increased gradually in half-gram increment until 1.5g, and colon 
rings were incubated in the bath system to equilibrate for about one hour until 
stablized. Then they were challenged with 60 mM KCl or 1 µM carbachol (C4382, 
Sigma-Aldrich, St. Louis, MO), a muscarinic agonist, to induce colon smooth 
muscle contraction. To determine the effect of calcium channel blocker on the 
induced contraction, L-type calcium channel inhibitor diltiazem (1µM, A2521, 
Sigma-Aldrich, St. Louis, MO) was admistered to the organ bath for 5 minutes 
before high KCl and carbachol stimulation.  
 
v. Contractility measurement of isolated thoracic aorta 
 
Thoracic aortas (about 0.5 cm) were dissected carefully and their branches were 
ligated with thread under microscope before being used. The aortas were 
mounted in the chamber filled with PSS aerated with mixed gas (22% O2-5% 
CO2-73% N2). The aorta was bridged to a PSS-filled tube that was pressurized 
with a regulator to inflate the vessels to the desired pressure before chemical 
stimulation. A pressure transducer (SPR-524, Microtip catheter transducer, Millar, 
Houston, TX) was used to monitor the intraluminal pressure, and a volume 
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compensator used to compensate for water transport across the vessel wall. A 
CCD camera on the microscope was able to convert the real-time image of the 
vessels to the computer for better visualization. The vascular contraction during 
endothelin 1 (ET1) stimulation was recorded as changes in intra-luminal pressure 
and quantitated using dimensional analysis software (DIAMTRAK 3, Australia) 
[156]. 
 
vi. Quantitative RT-PCR 
 
Total RNAs were extracted from colon smooth muscle, bladder and thoracic 
aorta of 6 weeks old control and smooth muscle-specific 130kDa MLCK knockout 
mice. The mRNA expression levels were quantitated by reverse transcription-
qPCR as described previously [157]. Because the 130kDa smMLCK transcript 
has a unique 5’ UTR region not present in the 220kDa MLCK transcript, we were 
able to take advantage of the unique region to design primers specifically 
detecting the 130kDa smMLCK mRNA. The primers used for the detection of 
220kDa MLCK, 130kDa MLCK and telokin are: 220kDa MLCK F: GAA CCT CTG 
CAT CAA AGA AGG AG, 220 MLCK R: GAT GGC TTG CCC TTT TCT GTG 
CCA TG, 130kDa smMLCK F: CTC TTG CTA CTT TCT CTT TTT CCT TCA CTG, 
130kDa smMLCK R: CTG GTC TCC ACC CGT CTC TTC AAC AG, Telokin F: 
GAC ACC GCC TGA GTC CAA CCT CCG, Telokin R: GGC TTT TCC TCA GCA 
ACA GCC TCC 
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vii. Western blot analysis 
 
Colon and bladder smooth muscle from both control and knockout mice were 
homogenized in the ice-cold glass tissue grind tube using the paired pestle. Total 
protein lysates from colon smooth muscle and bladder were extracted using 
radioimmune precipitation assay (RIPA) lysis buffer and protein concentrations 
were determined using a BCA protein assay kit (Thermo Fisher Scientific, 
Waltham, MA), as described previously [157]. 15µg of proteins was fractionated 
on 7.5% SDS polyacrylamide gels and transferred to nitrocellulose membranes. 
Antibodies used for detecting MLCK were a polyclonal antibody raised against 
the common carboxyl-terminus of MLCK and telokin (CT polyclonal, 1:5000) 
[158] and a polyclonal antibody raised against the full length bovine smMLCK (FL 
polyclonal, 1:1000) [159]. Vinculin was used as loading control (V4505, clone 
VIN-11–5, Sigma-Aldrich). Horseradish peroxide (HRP) conjugated goat anti-
rabbit secondary antibody (1:10,000) was used to detect and amplify the first 
antibody. Signal was developed using homemade enhanced chemiluminescnece 
solution (ECL) and quantitated on a G-box imaging machine (Syngene, 
Cambridge, UK). 
 
viii. MLC phosphorylation 
 
The proximal portion of the colon was cut into 0.5 cm-long circular rings, and the 
rings were hung in an organ bath, as described above for contractility 
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measurements of colon. Tissues were clamp flash frozen in liquid nitrogen at the 
basal non-contracted status or at the peak of contraction induced by 60 mM KCl 
and incubated in dry iced pre-cooled acetone denature buffer with dithiothreitol 
(DTT) and trichloroacetic acid (TCA) for one hour. Then the dried tissues were 
minced and proteins were extracted by votexing at low speed in urea gel 
extraction buffer containing 8 M urea, 20 mM Tris base, 22 mM glycine, and 10 
mM dithiothreitol. 15?l of the extracts were loaded onto 10% urea/glycerol gel to 
separate proteins for overnight. The bands for both unphosphorylated and 
phosphorylated myosin light chain (MLC) were visualized by Western blotting 
and the ratio of phosphorylated to total MLC was quantitated, as described 
previously [160]. 
 
ix. Cell proliferation 
 
The intestines of littermate neonatal mice (day 9-10) were dissected and the 
lowest portions of the ileum were incubated in 20% sucrose in PBS solution 
overnight at 4°C. Tissue samples were frozen into Tissue-Tek O.C.T. compound 
(Cat#4583, Sakura, Netherlands) and 7µm sections were cut. Sections were 
fixed with 3.7% formaldehyde, permeablized in 0.2% triton X-100 and blocked 
with 10% FCS in 50mMTris pH7.6, 150mM NaCl, then incubated with antibodies 
against Ki67 (Cat#15580, Abcam, Cambrige, UK, 1:500) and smooth muscle α-
actin (Cat#A2547, Sigma-Aldrich, St. Louis, MO, 1:500). Primary antibodies were 
visualized by incubation with rhodamine-conjugated Goat anti-Rabbit IgG 
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(Jackson ImmunoResearch, West Grove, PA, 1:50) and FITC-conjugated 
Donkey anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA, 1:50) 
secondary antibodies. The staining of the sections was observed under 
fluorescent microscope (Nikon, Tokyo). 
 
x. Statistical analysis 
 
Statistical comparison was performed by student’s t-test (Prism, GraphPad 
Software, La Jolla, CA). A value of p<0.05 was considered statistically significant. 
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D. Results 
 
i. Deletion of an intronic CArG element in the mylk1 gene abolished 
transgene expression driven by the 130kDa smMLCK promoter.  
 
Previously we reported a highly conserved CArG element located in intron 15 of 
the mylk1 gene (1st intron of the 130kDa smMLCK) [128]. To investigate the role 
of this intronic region in regulating 130kDa smMLCK gene expression, we 
generated transgenic mice in which a lacZ reporter gene was driven by the 
130kDa smMLCK promoter, exon1, intron1 and a portion of exon 2 with (ICArG-
smMLCK-389~+8427 pWhere) or without (ΔICArG-smMLCK-389~+8427 pWhere) this 
intronic CArG region, as described in Methods. In 2 of the 3 independent 
founders harboring the wild type transgene, high levels of β-galactosidase 
staining were observed in visceral smooth muscle rich tissues, such as bladder, 
colon, small intestine and ureters (Figure 8). The third line had lower levels of 
expression but in a similar pattern (not shown). One of the 2 high expressing 
founders also exhibited staining in bronchi as well as in the lung and small 
vessels of skeletal muscle and liver (Figure 8).  
 
In contrast to the wild type transgenes, no β-galactosidase expression could be 
detected in any of 7 founder mice harboring the CArG deleted transgene (Figure 
8). Weak background staining seen in bladder, kidney and colon is similar to that 
seen in non-transgenic mice (Figure 8, lower right panel). These data 
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demonstrate that the intronic CArG region is critical for expression of a 130kDa 
smMLCK-driven transgene.  
 
ii. Deletion of the intronic CArG region from the endogenous mylk1 gene 
resulted in decreased expression of the 130kDa smMLCK.  
 
To determine if deletion of the intronic CArG region would decrease expression 
of the endogenous 130kDa smMLCK, we crossed mice harboring the floxed 
CArG region with mice expressing cre recombinase under the control of the 
smooth muscle myosin heavy chain promoter (Figure 9) [161]. Both control 
(global heterozygous) and smooth muscle-specific CArG knockout mice reached 
adulthood without any obvious growth and behavioral abnormalities. However, 
knockout mice were born with a lower than expected frequency (19% versus 
25%, 50 out of 262, Figure 9C). This suggests that deletion of the intronic CArG 
region from the native gene results in partial embryonic lethality or neonatal 
death.  
 
Quantitative real-time RT-PCR showed that there was an approximately 40% 
decrease in 130kDa smMLCK mRNA levels in both colon and bladder of 
knockout mice, compared with control mice, while there was no significant 
alteration in 220kDa MLCK or telokin mRNA expression levels (Figure 10A). In 
addition, there was an approximately 30% reduction of 130kDa smMLCK mRNA 
levels in the aorta of knockout mice. Moreover, using an antibody to the common 
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carboxyl-terminus of MLCK and telokin, we found that deletion of the intronic 
CArG region reduced 130kDa smMLCK protein expression by approximately 
30% and 40% in colon and bladder, respectively (Figure 10B,C). Similar findings 
were observed using an MLCK antibody raised against the full-length bovine 
smMLCK (Figure 10C).  Additional experiments confirmed that the presence of 
the loxP sites in the control mice did not alter 130kDa smMLCK expression 
compared to wild type mice (data not shown).  
 
iii. Deletion of the intronic region and subsequent decreases in 130kDa 
smMLCK expression attenuated smooth muscle contractility.  
 
In order to investigate whether the decreased expression of the 130kDa 
smMLCK affects the contractility of both visceral and vascular smooth muscle, 
we analyzed the contractility of colon and aortic segments, ex vivo. Contraction 
elicited by high KCl-induced depolarization of colon from knockout mice was 
dramatically decreased compared with control mice (Figure 11A,C). Similarly 
carbachol induced contractions were also impaired in tissue from knockout mice 
(Figure 11B,C). L-type calcium channel inhibitor diltiazem markedly inhibited the 
contractile responses to both high KCl and carbachol (data not shown).  
 
ET1-mediated contraction of aortic segments was also decreased in knockout 
mice compared with control (Figure 11D) after a high concentration of ET1 
stimulation.  
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iv. Decreased contraction of smooth muscle tissues in knockout mice was 
associated with decreased myosin light chain phosphorylation.  
 
The 130kDa smMLCK induces contraction of smooth muscle by phosphorylating 
the regulatory myosin light chain. Thus we sought to determine if the impaired 
contractile responses seen in the knockout mice were associated with altered 
myosin light chain phosphorylation. Under basal resting conditions, levels of MLC 
phosphorylation in both control and knockout mice were very low and showed no 
significant difference (Figure 12).  However, at the peak of contraction induced by 
high KCl, the level of phosphorylation of the MLC in knockout mice was much 
less than that seen in control mice (18.3% as compared to 39.3%, Figure 12). 
 
v. Decreased 130kDa smMLCK expression resulted in shortened small 
intestine.  
 
Further analysis of both control and knockout mice showed that the length of 
small intestine was shorter by about 24% in the intronic CArG knockout mice, 
while the length of colon was not significantly different (Figure 13A, B). 
Consistent with this observation, immunofluorescence staining of cross-sections 
of ileum from neonatal mice for the cell proliferation marker Ki67 revealed that 
there were fewer positively stained smooth muscle cells in both circular and 
longitudinal smooth muscle layers of knockout mice (Figure 13C,D). Interestingly, 
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preliminary data showed there was more positive smooth muscle Ki67 staining in 
the ileum than that in colon or upper part of small intestine, suggesting it is likely 
after birth the ileum plays a major role in mediating the elongation of intestine. 
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E. Discussion 
 
Results of this study clearly show that a CArG box-containing region in intron 15 
of the mylk1 gene is required for expression of the 130kDa smMLCK. Deletion of 
this intronic CArG box attenuates expression of the 130kDa smMLCK without 
affecting expression of either the 220kDa MLCK or telokin. Moreover, decreased 
expression of only the 130kDa smMLCK in smooth muscle tissues attenuates 
smooth muscle contractility associated with decreased myosin light chain 
phosphorylation and impairs small intestine smooth muscle proliferation. This 
demonstrates that the 130kDa smMLCK isoform is specifically required to 
regulate not only smooth muscle contraction, but also intestinal smooth muscle 
cell proliferation.  
 
Deletion of the intronic CArG region completely abrogated expression of an 
smMLCK-lacZ reporter transgene in the visceral smooth muscle tissues, whereas 
deletion of this element from the endogenous gene only decreased endogenous 
130kDa smMLCK expression by about 40%. This would suggest that the reporter 
transgene is perhaps missing additional positive cis-acting regulatory elements 
that play a role in regulating expression of the endogenous 130kDa smMLCK. In 
support of this possibility a notch responsive element has been identified at  
-3687bp upstream of transcription start site and plays an important role in 
activating 130kDa smMLCK expression in vascular smooth muscle cells [162]. 
This element is not present in the reporter genes described in our study, which 
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extend from -389 to +8427. This may also explain why the reporter genes 
exhibited very low levels, or undetectable, LacZ expression in vascular smooth 
muscle tissues (Figure 9). Although the endogenous 130kDa smMLCK is 
expressed at lower levels in many nonmuscle tissues, we did not observe 
significant levels of lacZ transgene expression in many of these tissues. This 
may simply reflect the sensitivity of lacZ detection, although this may also reflect 
the nonnative chromatin environment of reporter transgenes. Although the 
transgenic reporter mice were generated using a pWhere lacZ expressing vector 
that is CpG-free and has H19 insulator elements flanking the transgene, we have 
previously shown that the telokin promoter also does not drive high levels of 
expression in many founder mice generated using this transgene vector [154]. As 
the promoter and regulatory elements analyzed are embedded within introns of 
the larger mylk1 gene it is possible that transcription from the promoters that 
drive expression of the 220kDa MLCK may modulate the chromatin structure of 
the gene to facilitate the activity of these internal elements. Although analysis of 
reporter genes suggest that the promoter and first intron of the 130kDa smMLCK 
are not sufficient to fully recapitulate expression of the endogenous 130kDa 
MLCK, deletion of the intronic CArG region from the endogenous gene 
decreases 130kDa smMLCK expression by 40%, demonstrating that this element 
is required for full activation of the gene. The region deleted following Cre 
recombinase mediated recombination of the lacZ reporter or the endogenous 
mylk1 gene includes a conserved CArG box together with almost 300bp of 
flanking sequence, We have previously shown that the CArG element is located 
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within a region of 63bp that is highly conserved between species [128]. This 
raises the possibility that the decreased 130kDa smMLCK seen following 
deletion of this region may be due to loss of not only SRF binding but also other 
as yet unidentified transcription factors.  
 
Through analysis of transgenic reporter mice and targeting the endogenous 
telokin promoter, we have previously shown that a CArG element within the 
telokin promoter is also critical for expression of telokin transcripts [163,164]. 
Together with the current findings these data show that SRF plays a key role in 
regulating expression of multiple transcripts from the mylk1 gene. Although SRF 
is important for regulating expression of both 130kDa smMLCK and telokin 
transcripts, it does so by binding to distinct CArG elements. These elements 
appear to be functionally separated from each other as deletion of a single CArG 
element affects expression of one transcript but not the other. Deletion of the 
CArG element in the telokin promoter (in mylk intron 28) abolished telokin 
expression without affecting expression of transcripts encoding the 200kDa or 
130kDa MLCKs [163]. Similarly, deletion of the CArG element from intron 1 of the 
130kDa smMLCK gene (in mylk1 intron 15) decreased expression of the 130kDa 
smMLCK without affecting expression of the 220kDa MLCK or telokin (Figure 10). 
These data would suggest that either the CArG elements are simply too far from 
the other promoters to affect their activity (e.g. the telokin CArG element is about 
73kb from the 130kDa smMLCK promoter) or that there are perhaps insulator 
elements within the mylk1 gene that restrict the activity of the elements to 
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specific promoters. Additional studies will be required to resolve these 
possibilities. 
 
Previous studies have shown that deletion of both the 220kDa and 130kDa 
MLCK from smooth muscle tissues impairs contractility, myosin light chain 
phosphorylation and impairs gastrointestinal motility in mice [150]. The current 
studies suggest that it is primarily the 130kDa smMLCK rather than the 220kDa 
MLCK that is responsible for regulating contraction in gastrointestinal smooth 
muscle. Results also suggest that the 130kDa smMLCK has a specific role in 
regulating the proliferation of small intestinal smooth muscle cells during early 
neonatal growth (Figure 13). Although MLCK and myosin light chain 
phosphorylation are known to be important in cell division this is the first data that 
demonstrate a specific role for the 130kDa smMLCK isoform in this process. 
 
In summary, data from both transgenic reporter mice and knockout mice models, 
demonstrate that a CArG region within intron 15 of the mylk1 gene plays an 
important role in specifically regulating expression of 130kDa smMLCK. The ICArG 
flox mice provide a novel model system for further interrogating the specific 
functions of the 130kDa smMLCK isoform in different cell types in vivo. 
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Figure 8. Comparison of transgene expression in different reporter mice  
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A. Organs were harvested from 1-month old reporter mice harboring the ICArG-
smMLCK-389~+8427 pWhere transgene (shown schematically at the top) and lacZ 
expression was examined by X-Gal staining (blue/green color, n=3). Yellow 
triangle, loxP site; black triangle, FRT site; blue box, intronic CArG element; red 
box, promoter CArG element.  
B. β-galactosidase expression in organs harvested from 1 month old mice 
harboring the ΔICArG-smMLCK-389~+8427 pWhere transgene (schematic, upper 
panel) in which the intronic CArG element is deleted (images are representative 
of 7 founder mice). Lower right panel shows β-galactosidase staining of colon 
from a nontransgenic mouse as a negative control (Negative colon).  
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Figure 9. Generation and genotyping of the intronic CArG knockout mice 
A. Schematic representation of approach used to delete the intronic CArG region 
from the endogenous mylk1 gene. The native mylk1 gene is shown at the top 
   66 
with the targeting vector below it. Numbers above the native gene refer to 
nucleotides positions relative to the transcription start site of the 130kDa 
smMLCK. The promoter and intronic CArG boxes are indicated (red and blue 
boxes, respectively). Yellow triangles, loxP sites; black triangles Frt sites. Below 
the targeting vector are schematic representations of the correctly targeted allele 
(Flox+Neo), the targeted allele following Flpe-mediated removal of the neomycin 
cassette (Flox) and the deleted allele generated following cre-mediated 
recombination (Deleted allele).  
B. Ethidium bromide stained agarose gel showing an example of the genotyping 
of the Flox mice using primers indicated by the arrows in panel A.  
C. Breeding scheme used to generate knockout mice together with the 
genotypes of the progeny, their expected frequency, observed frequency and 
total numbers of pups analyzed. 
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Figure 10. The expression of the 130kDa smMLCK is decreased in CArG 
knockout mice 
Smooth muscle layers were isolated from the indicated tissues of control (Ctrl) 
and knockout (KO) mice and total RNA or protein were harvested.  
A. The mRNA levels in colon, bladder and thoracic aorta from control and 
knockout mice were measured by qRT-PCR. Transcript levels were normalized 
to hprt internal loading control and relative expression levels (RQ) are shown. 
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Relative expression = 2-ΔDCt, where ΔDCt = (CtKO expt – CtKO hprt)-(CtCtrl expt – CtCtrl 
hprt). Each column represents the mean±SEM of samples obtained from 11-13 
mice. *, p<0.05.  
B. Representative western blot result of 130kDa smMLCK and vinculin in colon 
and bladder from two control (C) and two knockout (KO) mice.  
C. Quantitation of western blots using different antibodies for smMLCK. Data 
were normalized to Vinculin levels and are expressed relative to expression 
levels in control mice.  CT Ab: a polyclonal antibody raised against the common 
carboxyl-terminus of MLCK and telokin, FL Ab: a polyclonal antibody raised 
against the full-length bovine smMLCK. n=11-13. *, p<0.05. 
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Figure 11. The contractility of smooth muscle tissues from knockout mice 
is decreased.  
A-B. Colon rings were hung in an organ bath and stimulated to elicit contraction 
with 60mM KCl or 1µM Carbachol as described in methods. Data shown are the 
means ± standard deviations in tension over time of 20 rings from control mice 
and 12 from knockout mice. Red color denotes knockout mice and black color 
denotes control mice. 
C. The average changes in peak contractile responses of colonic rings from 
control (Ctrl) and knockout (KO) mice. n=20 for control, n=12 for knockout. *, 
p<0.05.  
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D. Mean maximal contractile responses of thoracic aortic to increasing doses (M) 
of Endothelin 1 (ET1). n=6 for control, n=5 for knockout. *, p<0.05. 
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Figure 12. The myosin light chain phosphorylation is decreased in 
knockout mice.  
Colon rings were either flash frozen under resting conditions or challenged by 
60mM KCl and flash frozen at the peak of contraction. Unphosphorylated and 
phosphorylated myosin light chains were separated by urea/glycerol gel 
electrophoresis and visualized by western blotting.  
A representative western blot is shown in the upper panel. (un-P, 
unphosphorylated MLC; P, phosphorylated MLC; C, control; KO, knockout).  
The ratios of MLC-P to total MLC under basal conditions (n=6) and after KCl 
stimulation (n=10) were calculated and the mean values±SEM are plotted. *, 
p<0.05. 
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Figure 13. Knockout mice have decreased smooth muscle cell proliferation 
and shorter small intestines.   
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A. Representative pictures and B, quantitative data showing the lengths of colon 
and small intestine of adult control and knockout mice. n=5. *, p<0.05.  
C. Ki67 (red) and smooth muscle α-actin (green) staining of cross sections of the 
lower portion of small intestines from neonatal control and knockout mice. White 
arrows and white arrow heads point to examples of Ki67 positive smooth muscle 
cells in the circular and longitudinal smooth muscle layers, respectively.  
D. Quantitation of the number of positive Ki67 smooth muscle cells per field at 
40x magnification in the circular layer, longitudinal layer and both smooth muscle 
layers of the small intestine. n=6-7 mice. *, p<0.05.  
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CHAPTER III 
REGULATION OF MICRORNAS BY BRAHMA-RELATED GENE 1 IN SMOOTH 
MUSCLE CELLS 
 
A. Summary 
 
MicroRNAs are involved in the phenotypic switch between differentiation and 
proliferation of smooth muscle cells. Brg1-containing SWI/SNF chromatin 
remodeling complexes also play an important role in controlling the phenotype of 
smooth muscle cells. We thus determined if Brg1 influences the transcription of 
microRNAs in smooth muscle cells. Microarray and qRT-PCR analysis of smooth 
muscle from mice harboring smooth muscle-specific deletion of Brg1 revealed 
altered expression of several microRNAs, including microRNAs-143/145 (miRs-
143/145) and miR-133. Dominant negative Brg1 attenuated miRs-143/145 
expression in wild type smooth muscle cells in vitro and myocardin-induced 
miRs-143/145 expression in 10T1/2 cells. In Brg1 null SW13 cells, miRs-143/145 
were dramatically induced by myocardin only in the presence of Brg1, while 
miRs-133 was not induced by myocardin in a Brg1-dependent manner. 
Knockdown of myocardin or serum response factor (SRF) in smooth muscle cells 
significantly reduced the expression levels of miRs-143/145 although miR-133 
expression was only attenuated by SRF knockdown. Chromatin 
immunoprecipitation assays demonstrated that myocardin in the presence of 
Brg1, increased the binding of SRF to the miRs-143/145 promoter as well as the 
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regulatory regions of miR-133. Together these data suggest a mechanism in 
which Brg1-containing SWI/SNF complexes are required for myocardin to induce 
expression of miRs-143/145 in smooth muscle cells. In contrast, miR-133 
expression appears to be regulated by Brg1-containing chromatin remodeling 
complexes in a partially SRF-dependent, although largely myocardin-
independent fashion. These observations together with what we reported 
previously imply that SWI/SNF-mediated chromatin remodeling regulates the 
phenotype of smooth muscle not only by directly affecting expression of smooth 
muscle-specific protein coding genes, but also by regulating expression of 
microRNAs that further modulate expression of these genes.  
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B. Introduction 
 
MicroRNAs are endogenous small non-coding RNAs (~22nt) which have 
emerged as key regulators of gene expression through inhibiting translation 
and/or promoting degradation of their mRNA targets. During microRNA 
biogenesis, primary microRNAs are first transcribed by RNA polymerase II from 
genes that lie either between or within protein coding genes. Primary microRNA 
transcripts are then sequentially processed by endonucleases Drosha and Dicer 
into mature microRNAs. MicroRNAs are widely expressed and exhibit tissue 
specific and dynamic expression patterns during development and 
pathophysiological processes.  
 
The importance of microRNAs in smooth muscle cell (SMC) differentiation and 
function has been demonstrated through analysis of mice lacking Dicer in these 
cells [165] [166] [114]. Deletion of Dicer in mouse smooth muscle cells by an 
SM22α promoter driven Cre transgene resulted in embryonic lethality at 
embryonic day 16 to 17 with underdeveloped vessels and extensive hemorrhage 
[165]. Deletion of Dicer in more mature smooth muscle cells mediated by smooth 
muscle myosin heavy chain (smMHC) driven Cre transgene did not result in 
embryonic lethality although the mice developed severe intestinal dysmotility with 
loss of the external smooth muscle layers [166]. Postnatal deletion of Dicer in 
SMCs using a tamoxifen regulated smMHC-Cre transgene resulted in a dramatic 
reduction of blood pressure and loss of contractile proteins within the vasculature 
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[114]. These studies demonstrate that microRNAs play a key role in the 
development and maintenance of SMCs in both vascular and gastrointestinal 
tissues. 
 
Among Dicer-dependent microRNAs, the most abundant in smooth muscle cells 
are miRs-143/145. MiR-143 and miR-145 are two mature microRNAs that are 
encoded by the same bicistronic primary microRNA transcript [167]. Although 
miR-143 and miR-145 knockout mice are viable, they have significant reduction 
in blood pressure, thinner smooth muscle layers, incomplete differentiation of 
SMC and altered neointima formation in response to vascular injury 
[167,168,169]. MiRs-143 and 145 have been shown to cooperatively modulate a 
network of targets via feed-back, feed-forward, or double-negative feedback 
mechanisms [170]. For example, miRs-143/145 can target Kruppel-like factor 4 
(Klf4), myocardin and member of ETS oncogene family (Elk1) [171], as well as 
versican [172] to promote differentiation and repress proliferation of smooth 
muscle cells. Moreover, several targets have been identified that regulate actin 
dynamics and cytoskeletal organization, such as myocardin-related transcription 
factor-B (MRTF-B), Adducin-3 (ADD3), Sling-shot 2 phosphatase (Ssh2), Slit-
Robo GTPase-activating protein 1 (Srgap1) and Srgap2 [167]. Using LacZ 
reporter mice, a 0.9-kb promoter region was shown to be sufficient to direct 
miRs-143/145 expression to cardiac and smooth muscle cells. Within this region, 
a highly conserved CArG element (SRF binding site) and Nkx2-5 binding region 
have been identified. Moreover, the miRs-143/145 gene is a direct transcriptional 
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target of SRF, myocardin and Nkx2-5, and it is up-regulated in more 
differentiated smooth muscle cells [171].   
 
Recently, miR-133, which is conventionally considered as a cardiac or skeletal 
muscle specific microRNA, has also been shown to inhibit VSMC proliferation in 
vitro and after balloon injury in vivo, at least partially through regulating the 
expression of Sp1 and moesin [123]. In cardiomyocytes, deletion of miR-133 
caused aberrant cardiomyocyte proliferation and ectopic expression of smooth 
muscle genes in the heart, partially through the up-regulation of miR-133 target 
genes SRF and cyclin D2 [173,174]. Moreover, Over-expression of miR-133 
reduced cardiac hypertrophy while inhibiting miR-133 resulted in hypertrophy 
[175]. In skeletal muscle, miR-133 has been shown to repress myogenesis but 
promote proliferation, partially through targeting SRF [174]. As SRF is a key 
regulator for skeletal, cardiac and smooth muscle development, it is likely that 
miR-133 might be an important regulator of all three muscle lineages. The miR-
133 isoforms miR-133a and miR-133b, are encoded by three genomic loci: miR-
133a-1, miR-133a-2 and miR-133b. Each of these loci is transcribed as a 
bicistronic primary transcript containing one miR-133 isoform with another 
microRNA [176]. In skeletal muscle cells, expression of these microRNAs is 
regulated by the myogenic factors MyoD and myogenin, and in cardiac muscle 
miR-133a expression is regulated by MEF2 [176,177]. Although the miR-133 
family members are now recognized as intriguing regulators of VSMC phenotypic 
modulation, little is known regarding the transcriptional regulation of these 
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microRNAs in smooth muscle cells. There is also little information on the 
epigenetic regulation of microRNAs in smooth muscle cells. In skeletal muscle 
cells, the Brg1 ATPase subunit of the SWI/SNF chromatin remodeling complex 
has been shown to be required for MyoD to activate transcription of both skeletal 
muscle contractile protein genes and miR-133a [127].  
 
Previously, it has also been shown that Brg1 is required for myocardin or 
myocardin related transcription factors (MRTFs) such as MRTFA to induce 
expression of smooth muscle-specific contractile proteins [109,178]. In current 
study we investigated the role of Brg1 in regulating microRNA expression in 
smooth muscle cells. Our results demonstrate that several microRNAs, including 
miRs-143/145 and miR-133, are regulated by Brg1 in smooth muscle. Brg1 is 
required for myocardin to induce binding of SRF to the regulatory region of miRs-
143/145, which is sufficient to activate its transcription. In contrast, the regulation 
of miR-133 expression by Brg1 requires more transcription factors than SRF 
itself. 
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C. Methods 
 
i. Animal use 
 
All the protocols for mouse experiments were approved by the Institutional 
Animal Care and Use Committee of Indiana University School of Medicine. To 
generate smooth muscle-specific Brg1 knockout mice, female Brg1flox/flox mice 
(obtained from C.-P. Chang at Stanford University) [179] were bred with male 
smMHC-Cre/eGFP mice (from Michael Kotlikoff at Cornell University) [180].  
Because of transient expression of Cre in the sperm of the male mice [181], the 
floxed allele transmitted from these male mice is recombined, thus there are four 
possible genotypes of the offsprings: Brg1f/- smMHC-Cre-/+ (SM-specific Brg1 
knockout with global heterozygous Brg1 background; “smBrg1 knockout”), 
Brg1f/- smMHC-Cre-/- (global Brg1 heterozygous, which we use as a control for 
the knockout mice), Brg1f/+ smMHC-Cre-/+ (SM-specific Brg1 heterozygous), 
and Brg1f/+ smMHC-Cre-/- (wild type). Genotyping was performed as previously 
described using primer TG57 and primer TH185 for Brg1 floxed and wild-type 
alleles, giving rise to the PCR products of 387bp and 241bp, respectively. Primer 
TG57: GCC TTG TCT CAA ACT GAT AAG, primer TH185: GTC ATA CTT ATG 
TCA TAG CC. Primers for Cre are: Cre F: CAT TTG GGC CAG CTA AAC AT, 
Cre R: CCC GGC AAA ACA GGT GTT A [182]. The global heterozygous Brg1 
mice (Brg1flox/-) were used as control mice, while smooth muscle-specific Brg1-
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null mice (smBrg1-/-) with global heterozygous Brg1 background were the 
experimental smBrg1 knockout mice.  
 
ii. Tissue harvest and RNA extraction  
 
Two months old control and knockout mice were sacrificed. Colons and bladders 
were dissected quickly and were put in cold PBS buffer on ice. The colon was 
cleaned, cut open longitudinally and then the epithelial layer removed by 
scraping with a scalpel. Bladder was washed in ice cold PBS. All the tissues 
were then frozen in liquid nitrogen immediately. To extract RNA from tissues, 
samples were first pulverized in liquid nitrogen and then homogenized in 
guanidinium isothiocyanate using a Polytron (Kinematica, Switzerland). Total 
RNA was extracted following standard protocols [183].  
 
iii. MicroRNA microarray  
 
Total RNA samples from colon smooth muscle tissues were checked for RNA 
integrity number (RIN) on Agilent Bioanalyzer (Agilent Biotechnology). Four 
samples from each group with RIN > 8 were then used for microarray analysis. 
Total RNA samples were labeled using the Genisphere FlashTag HSR kit 
(Genisphere, Hatfield, PA). The labeled samples were hybridized to Affymetrix 
GeneChip® miRNA arrays (Affymetrix, Santa Clara, CA). They were stained and 
washed using the standard microRNA protocol. Affymetrix GeneChip Command 
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Console Software (AGCC) was used to scan the arrays and generate CEL files. 
CEL files were imported into Affymetrix microRNA QC Tool to generate 
expression levels and detection calls. Probe sets that were absent in more than 
two samples for both controls and knockouts were removed prior to importing the 
expression levels into Partek Genomics Suite (Partek, St. Louis, MO) for analysis 
[184]. A t-test was performed using the log base 2 transformation of the 
expression levels. Fold changes were calculated using the raw expression levels.  
 
iv. Primary smooth muscle cell culture 
 
Primary colon smooth muscle cells were isolated from 1-month-old wild type 
C57/B6 mice. After colons were dissected, cleaned, and cut open, epithelial 
layers were removed by scraping. The smooth muscle layers were then minced 
in Hanks buffered saline solution (HBSS) on ice and digested with 0.6 U/ml 
Liberase TM (Roche, Indianapolis, IN) and 0.25 mg/ml DNase I (NEB, Ipswich, 
MA) in HBSS at 37°C for 45 minutes with shaking. The digested cells were 
filtered through a 100µm filter, washed in SMC growth medium (containing 
Dulbecco’s modified Eagle’s medium DMEM supplemented with 10% FBS, 2 mM 
L-glutamine, 50 units/ml penicillin, and 50 µg/ml streptomycin). Washed cells 
were plated in 6-well plates (1 well per colon) or SMC maintenance medium 
(containing Dulbecco’s modified Eagle’s medium DMEM supplemented with 1% 
FBS, 2% chick extract, 1% N2, 2% B27, 20ng/ml mouse bFGF, 100nM retinoic 
acid, 50nM β-mercaptoethanol, 50 units/ml penicillin, and 50 µg/ml streptomycin 
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and the medium was changed once per day until cells reached 100% confluence 
(usually about a week). Confluent primary cells were collected by trypsin 
digestion and plated in 6 or 12-well plates for adenoviral transduction.  
 
v. Expression plasmids and adenoviral transduction 
 
Human Brg1, Brm and dominant negative-Brg1 (DN-Brg1) plasmids were 
purchased from AddGene. MRTFA cDNA was purchased from Invitrogen. Mouse 
myocardin pcDNA3.1-myc/His vector was kindly provided by Dr. Eric N. Olson 
(UT Southwestern Medical Center, Dallas, TX). These plasmids were used to 
generate adenoviral expression vectors and adenoviral transductions were 
performed as described previously [109,178]. Adenovirus encoding nuclear 
localized yellow fluorescent protein (YFP) was used as negative control. 
 
vi. Quantitative RT-PCR 
 
Total RNA was extracted using Trizol reagent. MicroRNAs were quantitated 
using the small RNA quantitation system (SBI System Biosciences, Mountain 
View, CA) with some modifications. PolyA tails were added to the RNA by 
incubation with polyA polymerase at 37°C for 30 minutes. An oligo dT adaptor 
conjugated with a sequence complimentary to a universal reverse primer (CGA 
ATT CTA GAG CTC GAG GCA GG) was annealed to polyA-tailed RNAs at 65°C 
for 10 minutes followed by chilling on ice for 10 minutes. Then, cDNA was 
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synthesized and diluted as template for qPCR using microRNA specific forward 
primers (miR-143 forward primer: TGA GAT GAA GCA CTG TAG CTC, miR-145 
forward primer: GTC CAG TTT TCC CAG GAA TCC CT, miR-133a forward 
primer: TTT GGT CCC CTT CAA CCA GCT G, miR-133b forward primer: TTT 
GGT CCC CTT CAA CCA GCT A) and universal reverse primer. U6 snRNA was 
used as internal control. (Human U6 snRNA control forward primer sequence: 
CGC AAG GAT GAC ACG CAA ATT C, mouse U6 snRNA control forward primer 
sequence: TGG CCC CTG CGC AAG GAT G). The mRNA expression levels 
were quantitated through reverse transcription-qPCR as described previously. 
 
vii. Western blotting analysis 
 
Proteins were extracted with RIPA lysis buffer on ice. Protein concentrations 
were determined using a BCA Protein Assay kit (Thermo Fisher Scientific, 
Waltham, MA). 20µg of proteins were fractionated on 7.5 or 15% SDS-
polyacrylamide gels and transferred to nitrocellulose membranes. Membranes 
were then probed with a series of primary antibodies. Antibodies used for 
Western blotting were: β-actin antibody (Sigma, St. Louis, MO, 1:10,000), Flag 
tag antibody (Sigma, St. Louis, MO, 1:5,000) for exogenous Brg1 and Brm, HA 
tag antibody (M2, Covance, Princeton, NJ, 1:3,000) for exogenous MRTFA, 
Omni antibody (M-21, sc-499, Santa Cruz, Dallas, TX, 1:3,000) for myocardin. 
Primary antibodies were then detected using horseradish peroxidase-conjugated 
secondary antibodies and visualized using chemiluminescence. 
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Chemiluminescent signals were collected and analyzed on a G-Box imager 
(Syngene, Cambridge, UK). 
       
viii. Chromatin immunoprecipitation assays  
 
Chromatin immunoprecipitation assays using cells were performed as described 
[178]. Briefly, cells were fixed in 1% formaldehyde for 10 min at room 
temperature and harvested using cold PBS with protease inhibitors. After 
collecting cells by centrifugation, cell pellets were lysed using 1% SDS lysis 
buffer with protease inhibitors (200 µl lysis buffer/106 cells). For each group, 1 ml 
of lysate was sonicated at setting High with 30s burst and 30s silence for 9 
cycles in a bioruptor (Diagenode, Belgium) at 4°C.  The protocol for smooth 
muscle tissue chromatin immunoprecipitation assays was modified based on the 
one for cells. Specifically, tissues were finely minced before fixation. And the 
sonication condition for tissues was 45 cycles with 30s burst and 30s silence for 
each cycle. 200µl aliquots of chromatin were immunoprecipitated using 6µg of 
anti-SRF antibody (Santa Cruz, Dallas, TX), or rabbit IgG as negative control. 
The precipitated genomic DNA was purified and the presence of specific 
promoters was detected by real-time quantitative PCR, using gene promoter-
specific primers. Primers for the telokin promoter were used as positive control. 
Primers used were shown in Table 1.  
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D. Results 
 
i. Altered microRNA expression in smooth muscle tissues from smBrg1 
knockout mice.  
 
To determine which microRNAs are regulated by Brg1, we analyzed microRNA 
expression in smooth muscle tissues of control and smBrg1 knockout mice using 
Affymetrix GeneChip microRNA arrays. This analysis identified several 
microRNAs with decreased expression levels in knockout tissues, including miR-
133a, 133b and miR-206. Several microRNAs including miR-423-5p, 423-3p, 34a, 
28, 212, 674-5p exhibited increased expression in Brg1 knockout smooth muscle 
(>2-fold at a false discovery rate of <0.2). We did not observe a large change in 
expression of miR-143/145 in the array analysis, although miR-143 was 
decreased about 1.4-fold.  
 
Quantitative RT-PCR analysis of mature microRNA expression levels was used 
to confirm the microarray results. This approach revealed that in colonic smooth 
muscle tissues of smBrg1 knockout mice there was a significantly lower level of 
expression of miR-143, 145, 133a, 133b, 30a-3p as compared to tissues from 
control mice, while miR-34a, 28, 674-5p were significantly up-regulated (Figure 
14A).  
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Similar decreases in miR-143, 145, 133a, 133b were seen in bladder smooth 
muscle while only miR-28 was increased in bladders of smBrg1 knockout mice 
(Figure 14A). As miR-143, 145, 133a and 133b were decreased in both colon 
and bladder and these were the most abundant microRNAs analyzed in these 
tissues (Figure 14B), we focused on determining how Brg1 regulates the 
expression of these four microRNAs.  
      
ii. Brg1 regulates the expression of miRs-143/145 in smooth muscle cells.  
 
Altered microRNA expression observed in the tissues of smBrg1 KO mice could 
be a consequence of the pathological changes that occur in these mice as 
oppose to direct regulation of microRNA expression by Brg1. To distinguish 
between these possibilities, we introduced a dominant negative form of Brg1 
(K798R) (DN-Brg1) directly into cultured primary smooth muscle cells by 
adenoviral transduction. Consistent with a previous report [178], the DN-Brg1 
attenuated expression of smooth muscle markers such as smMHC, telokin, 
calponin (Figure 15A). The DN-Brg1 also attenuated expression of miRs-143/145, 
suggesting miRs-143/145 may be directly regulated by Brg1 (Figure 15B). 
Surprisingly, expression of miR-133a and 133b was not significantly affected by 
DN-Brg1 (Figure 15A).  
 
To further confirm the results, we cultured the primary colon SMCs from 
Brg1flox/flox mice and infected them with Cre-expressing adenovirus to delete Brg1 
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in vitro. After Brg1 was successfully deleted in primary SMCs, miRs-143/145 
were significantly decreased while not for miRs-133a/b (Figure 15B). These 
findings suggest that the attenuated expression of miR-133 observed in vivo, in 
the smBrg1 KO mice, may be a result of pathological changes rather than a 
direct affect of Brg1 on miR-133 expression. However, we noted that there is a 
very large decrease in miR-133 expression levels in the primary colon SMCs as 
compared to intact tissue such that expression is barely detectable (Figure 15C). 
The very low levels of expression may thus obscure the additional effects of the 
Brg1 on miR-133 levels in the cultured colon SMCs.  
      
iii. DN-Brg1 attenuates myocardin-mediated induction of miRs-143/145 and 
miR-133a.  
 
To circumvent problems resulting from lowered microRNA expression in primary 
SMC cultures, we examined microRNA expression in a cell system in which 
smooth muscle differentiation is induced. Over-expression of myocardin in 
10T1/2 cells has been previously shown to increase expression of most smooth 
muscle-specific genes and this increase can be blocked by DN-Brg1 [109,185]. 
Myocardin is a potent coactivator of SRF that is restricted to cardiac and smooth 
muscle tissues and is essential for vascular smooth muscle differentiation [186]. 
Myocardin has also been shown to induce expression of miR-143 in 10T1/2 cells 
[172]. We therefore used this system to examine the effects of DN-Brg1 on 
microRNAs. Similar to the smooth muscle-specific contractile proteins, 
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expression of miR-143, 145 and 133a were increased by myocardin and this 
induction was attenuated by DN-Brg1 (Figure 16). In contrast, myocardin did not 
induce miR-133b expression, implying that miR-133b may not be regulated by 
myocardin directly.  
       
iv. Knockdown of myocardin or SRF in primary SMCs attenuates miRs-
143/145 expression.  
 
To further examine the role of SRF and myocardin in regulating expression of 
miRs-143/145 and 133 in smooth muscle cells, we knocked down myocardin or 
SRF in primary SMCs using shRNA. The qRT-PCR analysis confirmed 
knockdown of myocardin and SRF and subsequent attenuated expression of 
smooth muscle-specific contractile proteins (Figures 17A,B). As expected, miR-
143 and 145 were reduced when either myocardin or SRF expression was 
knocked down (Figures 17A,B). In contrast, myocardin knockdown had no 
significant effect on miR-133a or 133b expression (Figure 17B), while SRF 
knockdown decreased expression of miR-133a and 133b (Figure 17A).  
         
v. Brg1 together with myocardin/MRTFA synergistically induces expression 
of miRs-143/145, but not miRs-133a/b.  
 
To further explore the role of Brg1 in regulating expression of microRNAs, we 
utilized SW13 cells lacking endogenous Brg1 or Brm expression. In these cells, 
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we found that myocardin or MRTFA’s ability to induce expression of miRs-
143/145 is dependent on Brg1 (Figure 18). SW13 cells were transduced with 
adenoviruses encoding Brg1, myocardin, MRTFA or YFP control. Western blots 
confirmed the successful expression of exogenous Brg1, myocardin or MRTFA in 
SW13 cells (Figure 18). Brg1, myocardin, or MRTFA alone did not dramatically 
influence the expression of any of the four microRNAs analyzed, whereas, Brg1 
together with myocardin or MRTFA robustly induced the expression of miR-143 
and miR-145 about 20 and 10-fold, respectively (Figure 18). Although myocardin 
alone up-regulated the expression of miR-133a about 2-fold this was not further 
enhanced by Brg1 (Figure 18). In contrast, miR-133b expression was not 
significantly affected by myocardin either in the presence or absence of Brg1. 
Together these data suggest that expression of miRs-143/145 is induced by 
myocardin or MRTFA in a Brg1-dependent manner, whereas miR-133a is only 
weakly activated by myocardin and miR-133b is refractory to myocardin and 
MRTFA activation. Similar results were obtained when Brm was used in place of 
Brg1 (data not shown). 
        
vi. Myocardin increases SRF binding to the miRs-143/145 promoter in a 
Brg1 dependent manner.   
 
Brg1 has been shown to enhance myocardin or MRTFA-mediated activation of 
smooth muscle-specific genes via facilitating SRF binding to their promoter 
regions [109,178]. As there is a potential SRF binding site in the promoter region 
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of miRs-143/5 locus, we thus determined if miRs-143/145 transcription was 
regulated in a similar manner. Binding of SRF to the promoter region of telokin 
was used as a positive control (Figure 19).  
 
In SW13 cells, over-expression of myocardin in the absence of Brg1 caused only 
a very small increase in binding of SRF to the miRs-143/145 (Figure 19). 
However, in the presence of Brg1, myocardin caused a much greater increase in 
the binding of SRF to the promoter regions of miRs-143/145 (Figure 19). 
Meanwhile, myocardin Brg1 binding to the promoter region of miRs-143/145 was 
not significantly changed by Brg1. Neither was Brg1 binding altered by myocardin 
(Figure 19). 
 
The ChIP data showed that Myocardin-mediated SRF binding to the miRs-133a 
promoter is also Brg1-dependent (Figure 19). However, the increase of SRF 
binding is not sufficient to drive the transcription of miR-133a, although it is part 
of the regulation machanism. Using bioinformatic tools, we found several other 
important transcription factors’ binding sites around the miR-133a loci, such as E-
box element, and MEF2 binding sites (Figure 19). However, they were not able to 
increase miR-133 expression either.  
 
vii. SRF binding to the regulatory regions of miRs is changed during SMC 
differentiation.  
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To further explore the SRF binding to the regulatory regions of miRs during 
differentiation, we utilized the myocardin-mediated SMC differention system from 
10T1/2 cells. ChIP assays showed increases of SRF binding to the promoters of 
miRs-143/145 and miR-133a (Figure 20). Only Brg1 binding to the miRs-143/145 
promoter was slightly enhanced during SMC differentiation. 
 
We also analyzed the SRF binding to the regulatory regions of miRs in the colon 
smooth muscle tissues between control and smBrg1 knockout mice. Consistently, 
SRF binding was also reduced when Brg1 was knocked out in smooth muscle 
cells (Figure 20). 
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E. Discussion 
 
Our current results demonstrate the SWI/SNF chromatin remodeling complex 
acts together with transcription factors and cofactors to regulate the expression 
of microRNAs in smooth muscle cells. SWI/SNF complex is required for 
myocardin or MRTFA to induce expression of miRs-143/145. These data, 
together with previous reports[109,178], suggest that Brg1 or Brm binding to 
myocardin or MRTFA recruits SWI/SNF to the miRs-143/5 promoter region, 
opening the chromatin structure thereby facilitating the tight binding of SRF to the 
promoter and subsequent transcriptional activation (Figure 21). Although Brg1 is 
also required for miR-133 expression in vivo and SRF is involved in the 
regulation of miR-133 expression, myocardin is a weak activator of miR-133a 
and does not significantly activate miR-133b, suggesting that Brg1 regulates 
miR-133 expression through other distinct mechanisms (Figure 21).  
 
The Brg1 and myocardin/MRTFA dependent regulation of miRs-143/145 is very 
analogous to the previously reported mechanism by which these proteins 
regulate expression of many smooth muscle-specific contractile proteins 
[109,178]. These findings are also consistent with previous studies that have 
shown that miRs-143/145 expression can be regulated by myocardin and SRF. 
Myocardin has been shown to be able to increase miRs-143/145 expression in 
cardiomyocytes [167] and 10T1/2 cells [172] and a CArG box within the miRs-
143/145 promoter has been shown to be required for reporter gene expression in 
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smooth muscle cells in vivo in mice [167,171]. The current studies extend these 
results to demonstrate that both myocardin and SRF are required for expression 
of miRs-143/145 in smooth muscle cells and that the SWI/SNF complex is 
required for myocardin-mediated induction of these microRNAs. These findings 
reveal that in smooth muscle cells the gene encoding miRs-143/145 is subjected 
to similar transcriptional and epigenetic regulation to genes encoding contractile 
proteins.  
 
The decreased expression of miRs-133a/b in vivo in smBrg1 knockout mice is 
consistent with previous studies that showed that Brg1 plays a critical role in the 
regulation of miR-133 expression in skeletal muscle. In skeletal muscle cells, it 
has been proposed that MyoD recruits Brg1 to E box sequences within the miR-
133a promoters [127]. As MyoD is restricted to skeletal muscle cells, clearly 
other transcription factors must recruit Brg1 to the miR-133 promoters in smooth 
muscle cells. Analysis of the regulatory regions of all three miR-133 genomic loci, 
revealed the presence of several highly conserved cis elements, including E box 
elements and potential binding sites for SRF and MEF2 (Figure 19). Knockdown 
of SRF in primary cultures of smooth muscle cells resulted in a small decrease in 
expression of both miR-133a and miR-133b suggesting that SRF may play a role 
in regulating expression of these genes in smooth muscle cells (Figure 17A). 
However, unlike miRs-143/145, expression of miR-133 genes was not 
significantly affected by myocardin knockdown (Figure 17B). In addition, 
myocardin was a very poor activator of miR-133a in SW13 cells and 10T1/2 cells 
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and miR-133b expression was completely refractory to myocardin stimulation in 
either cell type (Figure 17,18). The dramatic decrease in miR-133 expression 
seen in cultured smooth muscle cells (Figure 14C) suggests that results obtained 
from these cells should perhaps be interpreted with caution. The importance of 
SRF in regulating the expression of miR-133 thus remains to be determined in 
vivo. E-box binding proteins and MEF2, have been reported to play important 
roles in regulating expression of smooth muscle differentiation genes 
[187,188,189], however, the role of these proteins in regulating microRNA 
expression in smooth muscle has not been determined. As MEF2 has also been 
shown to bind to myocardin to autoregulate its own expression in cardiomyocytes 
[190] we evaluated the possibility that myocardin may cooperate with MEF2 
proteins to induce miR-133 expression. However, in the SW13 cell system MEF2 
proteins with or without myocardin were not able to induce miR133 expression 
even in the presence of Brg1. Similarly, E12/47 proteins with Brg1 were not able 
to induce miR-133 expression either. Additional studies will thus be required to 
determine the mechanism regulating the expression of miR-133 in smooth 
muscle cells. 
 
SWI/SNF complexes contain one of two alternative ATPases, Brahma-related 
gene 1 (Brg1) or Brahma (Brm). Both of these proteins are ubiquitously 
expressed in almost all tissues, and have both redundant and distinct functions in 
regulating gene expression. In vitro, both Brg1 and Brm can facilitate myocardin 
or MRTFA-mediated induction of smooth muscle-specific genes [109,178] and 
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miRs-143/145 (Figure 18 and data not shown). However, the knockout of Brg1 
alone in smooth muscle cells, in vivo, resulted in decreased expression of 
smooth muscle-specific contractile proteins and microRNAs in the 
gastrointestinal tract [182] (Figure 14). Thus, in vivo, Brg1 must have specific 
functions in smooth muscle cells that cannot be performed by Brm. Why there 
are specific requirements for Brg1 in vivo but not in vitro remains a mystery but 
may reflect expression levels of the proteins in vivo. In vitro, in over-expression 
experiments it is possible that Brm may be able to access complexes which Brm 
cannot access at normal expression levels in vivo. Specific functions of Brg1 
have also been revealed in other cell types. For example, Brg1 is specifically 
required for T-cell development [191]. Moreover, global Brg1 null mice die early 
in embryonic development due to growth arrest of the inner cell mass and 
trophoblast [192], while global Brm-null mice are viable and slightly larger than 
normal [193]. Knockout of Brg1 in smooth muscle cells in mice results in a myriad 
of defects including altered vascular remodeling leading to persistent ductus 
arteriosis and altered gastrointestinal contractility leading to intestinal blockage 
[182]. In addition to the described decreased expression of miRs-143/5 and miR-
133 in smBrg1 knockout mice, we also observed significantly increased levels of 
several microRNAs. This observation suggests that either these microRNAs are 
transcriptionally repressed by Brg1, or they are increased as a result of 
pathological changes that occur in the knockout mice. As DN-Brg1 did not 
increase expression of these microRNAs in smooth muscle cells in vitro (data not 
shown), it is probable that the changes observed in vivo are not a direct result of 
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Brg1-mediated repression. It is likely that the combined effects of altered 
expression of protein coding genes and microRNAs contribute to the complex 
pathology observed in the smBrg1 knockout mice. In support of this, miRs-
143/145 knockout mice have been shown to exhibit decreased vascular tone and 
decreased differentiation [167,169] suggesting that decreased expression of 
these microRNAs may be contributing to the impaired contractility observed in 
the smBrg1 knockout mice.  
 
In conclusion, we demonstrated for the first time that the SWI/SNF chromatin 
remodeling complex plays an important role in regulating microRNA expression 
in smooth muscle cells, in vitro and in vivo. Transcription of miRs-143/145 is 
regulated by SRF/myocardin complex, in a SWI/SNF chromatin remodeling 
complex-dependent manner. In contrast, expression of miR-133 genes appears 
to be largely myocardin independent. In smooth muscle cells, microRNAs and 
protein coding genes can thus be regulated by similar transcriptional and 
epigenetic mechanisms.  
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Figure 14. MicroRNA differences between control and Brg1 knockout mice  
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A. Total RNAs were extracted from colon (n=7) and bladder (n=6) of both at 6-8 
weeks old control (open bars) and Brg1 knockout mice (filled bars). The cDNA 
were generated and microRNA expression quantitated by real-time qPCR. 
MicroRNA expression was normalized to expression of U6 RNA as an internal 
control and is expressed relative to levels in control mice. Relative expression=2-
ΔΔCt, whereΔΔCt=(CtsmBrg1KO-CtU6)-(Ctcontrol-CtU6). * , p<0.05.  
B. Relative abandance of microRNAs in colon and bladder. Expression levels of 
miRs in colon and bladder from control mice are shown normalized to U6 RNA 
expression (n=6-7). * , p<0.05. Error bars, standard deviation. 
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Figure 15. Brg1-dependent changes in mRNAs and microRNAs in primary 
smooth muscle cells.  
A. Primary smooth muscle cells were collected from colon smooth muscle tissues 
of wild type mice and were transduced by adenovirus expressing YFP (open 
bars) as control (n=6) or DN-Brg1 (closed bars, n=5). Two days later, cells were 
lysed and total RNA isolated. The qRT-PCR experiments were performed to 
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compare the expression of smooth muscle markers and microRNAs. The mRNA 
and microRNA expression were normalized to HPRT and U6 internal controls, 
respectively, and then expressed relative to YFP control samples. Relative 
expression=2-ΔΔCt, where ΔΔCt=(CtDNBrg1-CtHPRT/U6)-(CtYFP-CtHPRT/U6).  
B. Primary smooth muscle cells were collected from colon smooth muscle tissues 
of Brg1flox/flox mice and were transduced by adenovirus expressing YFP (open 
bars) as control or Cre (filled bars) (n = 6). The mRNA and microRNA expression 
levels were quantitated as described in A.  
C. Comparison of microRNA expression levels in colonic smooth muscle tissue 
(open bars) and primary cultures of colonic smooth muscle cells is shown (filled 
bars). MicroRNA expression was normalized to expression of U6 internal control. 
*, p <0.05. Error bars, standard deviation. 
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Figure 16. Knockdown of myocardin or SRF in primary smooth muscle 
cells affects microRNA expression.  
A. Schematic representation of miR-133a and 133b loci. Conserved potential 
regulatory regions are indicated.  
B and C. primary colonic smooth muscle cells seeded in 6-well plates. 
Endogenous SRF (B) or myocardin (C) was knocked down by transduction with 
adenovirus encoding shSRF or shMyocardin, respectively (solid bars).  
A non-targeting shControl virus was used as control (open bars) (n=4-8). 48 h 
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later, total RNA was harvested. The mRNA and microRNA levels were 
quantitated by qRT-PCR as described in the previous figure and they were 
expressed relative to levels in shControl virus transduced samples.  
*, p <0.05. Error bars, standard deviation.
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Figure 17. Brg1-dependent changes in mRNA and microRNA expression 
during myocardin-mediated induction of smooth muscle cell differentiation 
in 10T1/2 cells.  
A, 10T1/2 cells were seeded in 6-well plates and transduced with YFP 
adenovirus or DN-Brg1 adenovirus, with or without myocardin (myo) adenovirus 
as indicated. 48 h later total RNA was harvested for qRT-PCR analysis to detect 
the expression levels of smooth muscle-specific genes and microRNAs as 
described previously, 10T1/2 cells were transduced with YFP (open bars) or 
myocardin (filled bars) adenovirus. Two days later, chromatin was harvested and 
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analyzed by ChIP assays for the binding of SRF and Brg1 to the CArG boxes 
indicated previously (n=4). ChIP samples were analyzed by real-time qPCR. 
Signals from immunoprecipitated samples were normalized to corresponding 
input samples and then presented relative to the signal obtained from the 
samples transduced with YFP adenovirus. Relative expression=2-ΔΔCt, where 
ΔΔCt=(Ctmyo-Ctinput)-(CtYFP-Ctinput). *, p < 0.05. Error bars, standard deviation.
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Figure 18. Brg1 and myocardin or MRTFA synergistically induce miRs-
143/145, but not miRs-133a/133b in SW13 cells.  
SW13 cells were transduced with YFP, Brg1, myocardin (myo), or MRTFA (MA) 
adenovirus alone or in combination, as indicated. 48 h after transduction total 
RNAs were harvested for qRT-PCR analysis as described previously (n = 6-8).  
*, p <0.05. Error bars, standard deviation.
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Figure 19. ChIP analysis of SRF, myocardin, and Brg1 binding to the CArG 
elements of the miR-143, 145, and 133a genes in SW13 cells.  
SW13 cells were transduced with adenovirus encoding YFP, Brg1, or myocardin 
(myo), as indicated. 48 h later, chromatin was harvested and analyzed by ChIP 
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assays using either an SRF, omni (to detect the epitope tag on myocardin), or 
Brg1 antibody or IgG control (n = 5–7). Specific primers were utilized to detect 
the CArG elements in the promoter regions of the telokin gene (data not shown), 
miRs-143/145 and miR-133a loci by quantitative PCR. Signals from 
immunoprecipitated samples were normalized to corresponding input samples 
and are then presented relative to the signal obtained from the samples 
transduced with YFP adenovirus as described previously.  
*, p < 0.05; ns, not significant (p >0.05). Error bars, standard deviation.
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Figure 20. ChIP analysis of SRF binding to the miR-143, 145, and 133a loci 
in colonic smooth muscle tissues from smBrg1 knockout mice.  
Colonic smooth muscle tissues were collected from control (open bars) and 
smBrg1 KO (filled bars) mice, and chromatin was harvested for ChIP assays (n = 
6). Chromatin was immunoprecipitated with an SRF antibody or IgG control. 
CArG elements within the miRs-143/145 and miR-133a loci were detected by 
qPCR. The qPCR signals from immunoprecipitated samples were normalized to 
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corresponding input samples. Relative expression=2-ΔCt, where ΔCt = Ctcontrol/ko-
Ctinput. *, p<0.05. Error bars, standard deviation. 
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Figure 21. Regulation of miRs-143/145 and miRs-133a/b by SRF and Brg1 
Schematic models (not to scale) show the mechanisms by which Brg1 regulates 
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miRs-143/145, miR-133a-1, miR-133a-2, and miR-133b loci. Myocardin 
promotes SRF binding to a single CArG box in the miRs-143/145 promoter in a 
Brg1-dependent manner that likely involves direct binding of myocardin to Brg1. 
This is sufficient to drive transcription of miRs-143/145 in smooth muscle cells. 
Only one of the two CArG boxes within each of the miR-133a loci binds to SRF in 
smooth muscle cells. Although myocardin can stimulate SRF binding to these 
CArG boxes in a Brg1-dependent manner this is not sufficient to stimulate miR-
133a transcription. Other transcription factors must act in concert with 
SRF/myocardin to drive miR-133a expression in smooth muscle cells. 
Expression of miR-133b is independent of myocardin but dependent on SRF. As 
we have previously shown that SRF does not bind to Brg1, Brg1 must regulate 
miR-133b expression through interactions with other transcription factors. Black 
boxes, miR stem loop structures; solid gray boxes, CArG elements; hatched 
boxes, E box elements; open boxes, potential MEF2 binding sites. 
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ChIP Primers 
human telokin ChIP F 
GTC AGC AAT AAG TCT TTG GAG 
CTG TCT CAG 
human telokin ChIP R 
ATG GCT CTC ACA GCA TTG CCC 
GTT TTC TGG 
mouse miR-143/145 CArG ChIP F CTAGCTCAGAGCAGCCTTG 
mouse miR-143/145 CArG ChIP R CCCGGGAGGGGTGAGAG 
human miR-143/145 CArG ChIP F AGCAAACTCTAACACTGTG 
human miR-143/145 CArG ChIP R GCCTTGCAAGCCACACTATC 
mouse miR-133a-1 CArG1 ChIP F TGTACTGGCCATATCAGGACAA 
mouse miR-133a-1 CArG1 ChIP R AACACTTCAACTGTCACCCTGA 
human miR-133a-1 CArG1 ChIP F CATATCGGGGCAAGGAGAG 
human miR-133a-1 CArG1 ChIP R CCTGACAGGGATAACAGATGC 
mouse miR-133a-1 CArG2 ChIP F TCTCTTGTGCCTCTCTCTTCC 
mouse miR-133a-1 CArG2 ChIP R CGACAATCGACAGCTGAGAG 
human miR-133a-1 CArG2 ChIP F GTGCCTCTCTCTTCCCTGAC 
human miR-133a-1 CArG2 ChIP R CTTCCTCAGCTTTTGGATCG 
mouse miR-133a-2 CArG1 ChIP F GCCCAGCTGACATGCTATTT 
mouse miR-133a-2 CArG1 ChIP R ATATACCCCGCCAAACATCC 
human miR-133a-2 CArG1 ChIP F CCCAGCTGACAGGCTATTTT 
human miR-133a-2 CArG1 ChIP R GCCAAGCATCCCAAACAC 
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mouse miR-133a-2 CArG2 ChIP F CCCATGAGCCCTCAATCAT 
mouse miR-133a-2 CArG2 ChIP R ATGACATGGGCAAGAGTGG 
human miR-133a-2 CArG2 ChIP F CCCTCTGTCATGCCCAGATA 
human miR-133a-2 CArG2 ChIP R GCTGAGAACGCGGACTATTT 
 
Table 1. Primers used for ChIP assay 
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CHAPTER IV 
CONCLUSIONS AND FUTURE STUDIES 
 
A. CArG-dependent regulation of smMLCK 
 
Results of my first project clearly show that a CArG box-containing region in 
intron 15 of the mylk1 gene is required for expression of the 130kDa smMLCK. 
Deletion of this intronic CArG box attenuates expression of the 130kDa smMLCK 
without affecting expression of either the 220kDa MLCK or telokin. Moreover, 
decreased expression of only the 130kDa smMLCK in smooth muscle tissues 
attenuates smooth muscle contractility associated with decreased myosin light 
chain phosphorylation and impairs small intestine smooth muscle proliferation.  
 
To extend these studies it would be interesting to determine if the altered 
intestinal contractility measured ex vivo translates to impaired intestinal motility in 
vivo. To achieve this, control mice and the knockout littermates would be orally 
administered contrast agent Gastrografin, then anesthetized for Computed 
Tomography (CT) to monitor the progress of the contrast agent through the GI 
tract over time. From this measurement I would be able to calculate GI transit 
time to determine if the decreased expression of the smMLCK impairs motility.  
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Similarly, to further evaluate the physiological effects of the observed decreased 
contractility of isolated aortic segments, it would be important to measure the 
basal and agonist-stimulated changes in blood pressure of both control and 
knockout mice in vivo. To do this I would use telemetry methods to record their 
blood pressure in vivo. The basal blood pressure as well as the agonist-
stimulated blood pressure (e.g. Angiotensin II) would be recorded continuously 
for several days to determine if the decreased expression of the smMLCK in 
vascular SMCs affects blood pressure.  
 
These additional studies together with my current fndings would solidfy the 
importance of the 130kDa smMLCK isoform in regulating smooth muscle 
contractility in vivo. This then raises the question of what are the functions of the 
220kDa MLCK in smooth muscle cells. Through specific targeting of a portion of 
the catalytic domain shared by the 220 and 130kDa MLCKs, it has been reported 
that ablation of both MLCK isoforms in smooth muscle cells resulted in impaired 
contractility and decreased myosin light chain phosphorylation [8,150]. Based on 
our data demonstrated in Chapter II, I think it is the 130kDa smMLCK that plays 
an important role in mediating smooth muscle contraction. However, to confirm 
that, I would generate smooth muscle-specific 220kDa MLCK null mice using a 
similar approach to the 130kDa intronic knockout mice and analyze smooth 
muscle contractility in control and 220kDa MLCK knockout mice as described 
above. 
 
   117 
In my study, I only carried out the research in SMCs. However, the intronic CArG 
floxed mouse we generated would be a great tool for interrogating the specific 
function of the 130kDa MLCK in other cell types, such as endothelial cells. In this 
case, Tie 2-Cre expressing mice would be mated with the intronic CArG floxed 
mice to generate endothelial cell specific 130kDa MLCK knockdown. With only 
the 130kDa MLCK isoform expression altered, it will be possible to determine the 
specific role of 130kDa MLCK in regulating endothelial cell functions.  
 
As I mentioned in Chapter II, a Notch responsive element has been identified at  
-3687bp upstream of transcription start site and plays an important role in 
activating 130kDa smMLCK expression in vascular smooth muscle cells [162]. 
However, this element is not included in the reporter gene described in my study, 
which extends from -389 to +8427. This may explain the reason why our reporter 
genes exhibited very low levels, or undetectable LacZ expression in vascular 
smooth muscle tissues. To confirm this, I would utilize a reporter gene, 
containing the region from -3687 Notch responsive element to +8427, to 
generate the reporter mice. Analysis of the reporter mice in a similar manner to 
that in my study would demonstrate the role of the upstream Notch responsive 
element in directing gene expression in vascular SMCs.  
 
B. Transcriptional and epigenetic regulation of microRNAs in SMC 
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Data described in Chapter III demonstrate the SWI/SNF chromatin remodeling 
complex acts together with transcription factors and cofactors to regulate the 
expression of microRNAs in smooth muscle cells. Specifically, SWI/SNF complex 
is required for myocardin or MRTFA to induce expression of miRs-143/145, so 
that it further opens the chromatin structure thereby facilitating the tight binding of 
SRF to the promoter and subsequent transcriptional activation. Although Brg1 is 
also required for miR-133 expression in vivo and SRF is involved in the 
regulation of miR-133 expression, myocardin is a weak activator of miR-133a 
and does not significantly activate miR-133b, implying that Brg1 regulates miR-
133 expression through other distinct mechanisms. 
 
Although these studies have provided new information on the regulation of 
microRNA expression in smooth muscle cells, a number of key questions remain 
to be answered as detailed below. 
 
i. What other transcription factors regulate transcription of miR-133 in 
VSMCs?  
 
Although Brg1 is also required for miR-133 expression in vivo and SRF is 
involved in the regulation of miR-133 expression, myocardin does not 
significantly activate miR-133b, implying that Brg1 must regulate miR-133 
expression through other distinct transcription cofactors rather than myocardin. 
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In addition to SRF, highly conserved E-box elements and MEF2 binding sites are 
present in the regulatory region of miR-133.  
 
To determine if these sites are important for regulating miR-133 expression, I 
would first determine whether these transcription factors are able to bind to the 
cis-acting elements within SMC by chromatin immunoprecipitation (ChIP) assays 
using antibodies specific for transcription factors MEF2, and E-box binding 
proteins E12, HEB, E2-2, E47, USF1, USF2. Once any trancription factor is 
proved to be able to bind to regulatory region, the importance of the predicted 
transcription factor binding sites for the transcription of miR-133 would be tested 
by luciferase assays. To do this, luciferase reporter genes containing mutations 
in each of the identified cis-acting elements would be generated and transfected 
into SMCs and luciferase activity measured. Finally to determine if specific 
transcription factors are important for the expression of miR-133, I would 
knockdown expression of these proteins in primary SMCs and examine the 
subsequent changes in miR-133 expression by qRT-PCR.  
 
ii. How does Brg1 act together with the identified transcription factors to 
regulate expression of miR-133 in SMCs? 
 
Once potential transcription cofactors are identified, I would thus determine if the 
transcription factors serve to recruit Brg1 to the miR-133 gene by direct 
interaction between the transcription factors and Brg1. This would be revealed by 
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co-immunoprecipitation assays and chromatin immunoprecipitation assays. The 
former experiments would be able to identify whether Brg1 physically interacts 
with the identified transcription factors. For the latter experiments, I would 
knockout the transcription factors and utilize the specific antibody against Brg1 to 
pull down the protein complex together with bound DNA fragments. I would 
perform PCR to amplify the targeted regulatory element using designed primers 
flanking the binding sites and then the amount of Brg1 bound to the regulatory 
region with or without the identified transcription factors would be compared.   
 
Once I have determined how chromatin remodeling complexes are recruited to 
the microRNA genes I would then confirm the functional importance of these 
intereactions using the SW13 cell system described in Chapter III. In this 
experiment, Brg1 and/or transcription factor candidates would be over-expressed 
in SW13 cells. RNA would be extracted and expression of miR-133 would be 
determined by real-time PCR. This approach will allow me to determine if specific 
transcription factors can induce miR-133 expression in the presence or absence 
of Brg1.  
 
After I have established how expression of miR-133 is regulated using these in 
vitro systems the next step would be to test this in vivo. Idealy, to do this the 
identified specific transcription factor would be knocked out from smooth muscle 
cells in mice and the resultant affects on miR-133 expression would be 
determined. 
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Together, my data suggest that similar to SMC contractile protein genes, there 
exists fine regulation of microRNA expression in SMCs. MicroRNAs have 
constituted a new layer of gene regulation for fine tuning the phenotype of 
smooth muscle cells. As miR-133 has been linked to SMC phenotypic switch 
during vascular diseases, unraveling the mechanisms controlling its expression 
will provide a better understanding of the mechanisms causing atherosclerosis 
and vascular restenosis. One could envisage the development of novel therapies 
targeting specific transcription cofactors that control expression of microRNAs to 
selectively fine-tune smooth muscle-specific gene expression and ameliorate or 
reverse pathological changes in smooth muscle cells that occur in many 
diseases.  
 
C. Overall summary 
 
In summary, my research demonstrates that through direct interaction with a 
CArG box in the mylk1 gene, SRF is important for regulating expression of 
smMLCK to control smooth muscle contractility. In addition, SRF is able to 
harnesses epigenetic mechanisms to modulate expression of smooth muscle 
contractile protein genes directly and indirectly via changes in microRNA 
expression. Together these mechanisms permit SRF to coordinate the complex 
phenotypic changes that occur in smooth muscle cells. Furthermore, the ICArG flox 
mice provide a novel model system for further interrogating the specific functions 
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of the 130kDa smMLCK isoform in different cell types in vivo. Also, unraveling 
the genetic and epigenetic mechanisms that regulate microRNA expression in 
smooth muscle cells will help to fill the existing gap in our knowledge and 
broaden our understanding of the importance of non-coding RNAs in SMC 
pathophysiology.
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